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Abstract
Pancreatic cancer (PC) remains a significant, unresolved issue because of its complex
genetic blueprint and lack of reliable detection markers. The purpose of this study was to
examine the possible correlation between tobacco use, gender, and age in the
etiopathogenesis of PC and other cancer types with a shared-gene association (CTSG-A).
The unified paradigm of cancer causation was used to understand the pathopoiesis
mechanism of smoking and shared genes in PC. A cross-sectional study was performed
using secondary data from the cancer survivorship module of the 2014 Behavioral Risk
Factor Surveillance System survey. Results of ordinal logistic regression analyses
indicated no correlation between smoking and prevalence of PC and CTSG-A, but gender
and age were significant predictors. Gender has a statistically significant effect on the
prediction of PC/ CTSG-A induction and promotion. Increased probability of developing
the disease was found as the person reach the age between 62 and 69 years of age.
Findings may enhance the understanding of environmental, genetic, and biodemographic
interactions in disease evolution (induction, promotion, and expression periods). Findings
may also be used to promote population health and improve health behaviors for
individuals in vulnerable, high-risk groups.
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Chapter 1: Introduction to the Study
To raise new questions, new possibilities, to regard old problems from a new
angle requires creative imagination and marks the real advance in science (Einstein &
Infeld, 1938, p. 92). Pancreatic cancer (PC) at the start of the 21st century continues to be
a vital unresolved health problem, remaining as one of the deadliest human cancers.
Although genetic changes can be either somatic or hereditary, described as de novo
(new), PC does not arise de novo (Maitra & Hruban, 2008), but rather initiated by a
probable gene mutation such as p16/CDKN2A that results to debilitating metabolic
effects of uncontrolled growth. The five-year survival rate of less than 5% of PC is a
statistic that remains constant for many years (Garcia et al., 2007; Hidalgo, 2010;
Makohon-Moore, Brosnan, & Iacobuzio-Donahue, 2013). Hoeijmakers (2009) stated that
the damage to the DNA is the causality of the development of PC, and continued inquiry
is paramount to understand the principles of its cancer biology. Zakharova,
Karmazanovsky, and Egorov (2012) found that the minor populations of cells with stemlike properties had been identified and appear responsible for the development and
progression of pancreatic cancer. According to Hruban Canto, Goggins, Schulick, and
Klein (2010), although some of the aggregation of PC arises from environmental factors
such as tobacco use, aggregation of the disease in families could be due to chance and
genetics.
There are three ways that DNA can be mutated: inherited mutation in the context
of genetic predisposition or susceptibility, DNA mutation caused by behavioral risk
factors, and DNA damaged by chance (Couch et al., 2007; Irigaray et al., 2007; Jones et
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al., 2009). Even if an individual has an inherited syndrome or inherited predisposition, a
person with one good copy of the cancer-associated gene may or may not develop the
disease (Suter, 2015). Given the assumption that a disease is caused by a factor that can
be controlled, exploring the relationship between modifiable health behaviors such as
smoking and family cancer history (FCH), cancer predisposition genes (CPG) or shared
genes was a legitimate endeavor. In this study, genetic syndromes associated with PC
were interchangeably referred to as FCH, CPG, or shared genes. Understanding of the
biology of PC has progressed over the years, including advances in patient management.
According to Vincent, Herman, Schulick, Hruban, and Goggins (2011), the evidence is
starting to show that first-degree screening relatives of individuals with several family
members affected by PC can identify noninvasive precursors of this lethal disease.
Vincent et al. demonstrated the incidence of and the number of deaths caused by
pancreatic tumors had been gradually rising, even as incidence and mortality of other
common cancers have been declining. The poor response to most chemotherapeutic
agents among patients with advanced unresectable PC (Vincent et al., 2011) highlights
the need for more effective control of tumor initiation and metastasis, and for a better
understanding of the evolutionary framework of the disease.
Exploring the Darwinian nature of PC could lead to improvement in conventional
therapies. Vincent et al. (2011) justified the significance of understanding the biological
mechanisms contributing to the development and progression of pancreatic tumors. Klein
et al. (2004) highlighted the importance of quantification of the risk of individuals with
shared genes as a basis for cancer risk screening and counseling. In this cross-sectional
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study, the quantification of PC risk among Behavioral Risk Factor Surveillance Survey
(BRFSS) participants diagnosed with the disease supported the assumption of increased
risk in association with shared genes and shared environmental factors such as smoking.
Given Blackford et al.’s (2009) findings regarding the nonspecific DNA damage caused
by tobacco carcinogens, I examined the correlation between tobacco carcinogen-related
mutations, inherited cancer predisposition, and new cases of pancreatic cancer. The social
change implications of this study depended on the success of quantifying the association
between smoking and CPG, highlighting the importance of tobacco-use cessation as a
lifestyle and health-enhancing behavioral change. Although findings may not have
indicated an association between tobacco use and CPG in the development and
progression of PC, including gender and age, the study amplified the need for smoking
cessation programs and cancer-specific profiles.
Background
Tersmette et al. (2001) and Reznik, Hendifar, and Tuli (2015) examined the risk
of developing PC among first-degree relatives in families with the disease using the
National Familial Pancreas Tumor Registry (NFPTR). Hruban et al. (2010) confirm the
elevated risk level of both pancreatic and extrapancreatic malignancies to individuals
with a family history of PC. Although the genetic basis of more than 80% of the
clustering of pancreatic cancer in families remains unknown, Hruban et al. addressed the
significance of the resultant flood of information that could be generated by investigators
at Johns Hopkins University in sequencing candidate familial pancreatic cancer genes.
The findings strengthened the NFPTR through aggregation of data from international
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screening and surveillance by a consortium of 25 countries. Likewise, the 2013 study by
Canto et al. supported the importance of screening, surveillance, and management of
high-risk individuals with an inherited predisposition to PC. Reznik et al. (2015) also
discussed the future directions and usefulness of screening for individuals with familial
pancreatic cancer. Similarly, Bartsch, Gress, and Langer (2012); Brand et al. (2007);
Canto et al. (2013); and Klein (2012) discussed the practicality of screening swirled on
individuals who are carriers of a mutation in an established high-penetrance pancreatic
ductal adenocarcinoma (PDAC) susceptible genes—BRCA2 (BReast CAncer gene two)
and PALB2 (Partner and Localizer of BRCA2).
Prokopczyk et al. (2002) and Ding et al. (2008) investigated the combined
causality of non-tobacco-related mutagenic risk factors such as the inherited
predisposition to cancer that may share mutagenic properties with the tobacco mutagens.
Debates over the current knowledge of modifiable risk factors, such as smoking, tend to
dominate in the likelihood of increased probability of developing the disease. Schulte et
al. (2014) elaborated the smoking component primarily relevant to pancreatic cancer risk
(PCR). After analyzing data from the Queensland Pancreatic Cancer Study, the result
provided the evidence that in addition to dose effect of tobacco use, the smoking pattern
may affect PCR. The body of knowledge given by these researchers justifies the purpose
of this dissertation in examining the association between smoking and the initiation and
progression of the disease in an individual with FCH. Breitkopf et al. (2012) confirmed
the importance of addressing behavioral and genetic risk factors for PC, parallel to the
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association of gender and age, supporting the value of this dissertation in addressing the
dearth of existing data on the etiopathogenesis of the disease.
Current State of Understanding
The pancreatic cancer putative cell of origin remains elusive despite the
progressive increase in the understanding of pancreatic carcinogenesis from intensive
histologic and genomic research (Maitra & Hruban, 2008). Patients diagnosed with PC
stay asymptomatic until the progression of the disease propelled at an advanced stage,
making PC stand out among the most lethal malignancies (Braat, Bruno, Kuipers, &
Peppelenbosch 2012; Siegel, Naishadham, & Jemal, 2012). Moreover, this disease often
mimics other benign conditions, making this disease one of the most challenging cancers
to detect and treat (Lowenfels & Maisonneuve, 2006). Tobacco use remains the most
well-established risk factor for PC (Maisonneuve & Lowenfels, 2015), and since the
1970s, smoking cessation has become the primary tool for reducing the risk of the
disease. From 2008 to the present, investigators such as Petersen et al. (2010) focused on
mapping the pancreatic cancer genome and identified common susceptibility loci for PC
that warrant follow-up studies. The primary reasons behind poor prognosis are early
metastasis, chemo resistance, and late clinical outcomes, making PC the fourth leading
cause of cancer-related death globally (Malhotra, Ahn, & Bloomston, 2015). Given the
heterogeneous nature of PC etiology with an extensive variety of modifications (Thomas
et al., 2014), the pancreatic tumor genome sequencing provides a path-breaking
opportunity in mapping smoking-related mutational patterns.
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Accumulating evidence indicated that carcinogenic tobacco compound
contributes to the development of pancreatic cancer (Pandol, Apte, Wilson, Gukovskaya,
& Edderkaoui, 2012). Blackford et al. (2009) argued that smokers could develop a bigger
number of mutations than nonsmokers, doubling the risks that record for 20 to 25% of
pancreatic cancers. The types and mutational patterns observed among smokers in
Blackford et al.’s study gave additional insights on the pathopoiesis component by which
cigarette smoking causes PC induction and promotion. Parallel to Blackford et al.’s
conclusion on the impact of tobacco use in increasing the risk of pancreatic growth
through components other than genetic mutations, Porta et al. (2009) found that tobacco
smoking increases the risk of PC through events other than Kras mutations. After the
researchers had evaluated all of the available types of epidemiological and clinical studies
on the occurrence of V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)
mutations in human adenocarcinomas in correlation to smoking, the results supported the
hypothesis that tobacco use influences the risk of PC.
Problem Statement
Pancreatic cancer has been estimated to have higher mortality rates, with an
economic encumbrance of $4.9 billion annually (Pandol et al., 2012). The prognosis of
pancreatic cancer remains dismal despite the substantial progress in the understanding of
PC biology. Germline mutation makes up 5% to 10% of all cancers, and of the germline
gene mutations that have been identified to increase PC risk, mutations in BRCA2
account for up to 17% of familial pancreatic cancer (FPC) kindreds (Murphy et al., 2002;
Hahn et al., 2003; Couch et al., 2007). As genomic sequencing technologies have
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decreased in cost and become more commonplace, there has been much to learn
regarding differential sensitivities of various DNA damage response (DDR) gene
mutations, such as somatic versus germline and new mechanisms of treatment resistance
(Carnevale & Ashworth, 2015). Although genetics may play a role in disease
development, the procarcinogenic effect of smoking is considered the precursor to the
development and progression of pancreatic cancer according to Vincent et al. (2011).
Both Blackford et al. (2009) and Schulte et al. (2014) highlighted the association of
smoking pattern in the increased risk of the disease. Although Schulte et al. confirmed the
magnitude of dose effect of smoking to the disease, Blackford et al. failed to establish a
characteristic profile of the number of tobacco carcinogen-related mutations within the
pancreas (tail vs. head), tumor grade, patient’s age, sex, margin status, and stage.
Although the treatment combinations of surgery, radiotherapy, and chemotherapy could
improve the chance of survival and quality of life, continued research in establishing a
unique pattern on the pathobiology of PC malignancy among patients who have a history
of smoking and shared genes is warranted.
Given the evidence that PC, like most human cancers, contains multiple
mutations, continued research is needed to advance the understanding of the essential
principles of its cancer biology (Hoeijmakers, 2009). Although the Darwinian nature of
PC makes the prediction of its evolution virtually impossible (Lennon et al., 2014),
smoking often has a multiplicative increase in PC risk when combined with other risk
factors such as alcohol, recent onset diabetes, and family history (Jansen, Tan, &
Petersen, 2015; Schenk et al., 2001). Carcinogens from tobacco such as N-nitrosamines,
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benzo(a)pyrene, polycyclic aromatic hydrocarbons, A-napthylamine,
methylfluoranthenes, and arylamines are capable of forming DNA adducts that increase
the risk of somatic mutations and PC (Jansen et al., 2015; Suwan-ampai, Navas-Acien,
Strickland, & Agnew, 2009; Vrieling et al., 2010). In addition to an increasing amount of
research regarding dynamic epigenetic processes and their role in gene regulation (Jansen
et al., 2015), past and present epidemiologic studies such as Yang et al. (2012) indicated
a significant interaction between smoking and cytotoxic T-lymphocyte-associated protein
on the risk of PC.
Jansen et al. (2015) underscored the significance of genetic data that can assist in
identifying individuals at high risk of developing PC, which confirms the need for new
statistical and epidemiological methods to pinpoint the responsible genetic variants and
their interaction with modifiable risk factors. Tobacco use is a modifiable risk factor that
has been studied extensively (Iodice, Gandini, Maisonneuve, & Lowenfels, 2008).
Taking into account the gene-environment interaction with modifiable risk factors such
as tobacco use is the cogent step to understanding the epidemiology and pathometry of
PC. The unique contribution of this dissertation to the current body of knowledge
involved examining the links between tobacco use, gender, age, PC, and shared genes.
This dissertation could promote population health, and lessons learned could reshape the
current understanding of cancer epidemiology by providing the scientific justification for
the implementation of screening, surveillance, and education programs. The outcome of
this dissertation would fit into the practical intervention approach of adopting a healthy
lifestyle such as smoking cessation as part of positive, meaningful social change to
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improve prognosis and quality of life during PC progression. Like the Pancreatic Cancer
Detection Consortium (PCDC), the principal intent of this dissertation was in response to
the Recalcitrant Cancer Act, signed into law on January 2, 2013, after strong bipartisan
support for President Barack Obama. The outcome of this study could support the 21stcentury thinking that underscores the influence of modifiable risk factors in relation to
healthy lifestyle choices in lowering the risk of developing pancreatic cancer. The
mechanism through which the role of smoking in augmenting the development or
accelerating the progression of PC to individuals with FCH, CPG, or shared genes needs
a well-grounded inquiry for new complementary/alternative research direction that will
underpin the existing body of knowledge. In response to the need to enhance the
understanding of PC epidemiology, this dissertation will address the gap in exploring the
interaction between shared environmental factors (tobacco use) and shared genes, as well
as the role of gender and age as explanatory variables.
Purpose of the Study
PC is a complex and highly lethal disease, best treated in a multidisciplinary
setting. The grim survival statistics of PC justify the intent of this dissertation to establish
clarity about the pathopoiesis mechanism of tobacco use and CPG or its combined role in
the etiopathogenesis of the disease. There are numerous studies on the association of
relevant risk factors for PC, but there are limited studies linking smoking level to CPG or
FCH. Schottenfeld and Fraumeni (2006) and Silverman et al. (1994) asserted that
smoking exhibits its biologic effects on both early and later stages of the carcinogenic
process. The purpose of this dissertation was to establish clarity on the role of tobacco
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use in the development of PC among individuals with FCH, cancer predisposition gene
(CPG), or shared genes. Because the size of the primary lesion has a correlation with
long-term survival, the innate metastatic propensity of this disease needs further study
addressing the behavior, prevention, and mechanisms associated with pancreatic cancer
risk (Chari et al., 2015; Perera & Bardeesy, 2015). Although it is important to treat a
complex and highly lethal disease like PC in a multidisciplinary setting, Wolfgang et al.
(2013) asserted that the prevention of an invasive PC is dependent on the improvements
in the management of cystic pancreatic lesions.
Research Questions
Pancreatic cancer and other cancers found to have a shared-gene association (SGA) were the dependent variables, and smoking status, age, and gender were the
independent variables; this study addressed the following research questions (RQs) and
hypotheses:
RQ1: Is cigarette smoking associated with the etiopathogenesis of pancreatic
cancer and cancer types with shared gene association (CTSG-A)?
H01: Smoking level has no correlation with prevalence of PC and CTSG-A.
H1: Smoking can increase the risk of PC and CTSG-A.
RQ2: Is there a relationship between the combined role of age and gender in the
etiopathogenesis of PC and CTSG-A?
H02: Age and gender have no correlation with prevalence of PC and CTSG-A.
H2: Age and gender are correlated with the prevalence of PC and CTSG-A.
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Chapter 3 provides a more detailed discussion of the objectives, research questions,
hypotheses, and analysis plan.
Theoretical Basis for the Study
To properly frame the hypothesis that tobacco use, gender, and age in
combination with inherited mutation could increase the risk of developing PC and CTSGA, a metatheory was appropriate to unriddle the axiom of biologic synergism and the
link of a causal modifiable risk factor. Based on Rothman’s (1986) notion of
epidemiologic interaction, the biologic synergism explored in this dissertation was the
sufficient cause of tobacco use (A) and cancer predisposition gene or FCH (B); if both
are present, there is an increased risk of PC. Although the sufficient cause paradigm
could also help support a working hypothesis that individuals with inherited mutations
have a higher risk for the disease without A, the presence of A or act in combination with
B could mean a probable higher cause of malignancy. On the other hand, removal of A
implies that the probable additional mutations caused by exposure to A could eliminate
the sufficient cause of A in the etiopathogenesis pathopoiesis (see Figure 1).
Knudson’s two-hit theory of cancer causation may be appropriate in explaining
the pathopoiesis mechanism involved in FCH. However, the Unified Paradigm of Cancer
Causation (UPCC) as the proposed metatheory in this dissertation could provide
arguments on the positive association (synergism) between tobacco use and FCH, giving
more clarity to Rothman’s notion of epidemiologic interaction or the paradigm of
sufficient cause. UPCC is a composite construct of the germ theory and the somatic
mutation theory of carcinogenesis (SMT) in combination with the traditional or
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Darwinian evolutionary system (Greaves & Maley, 2012), Knudson’s two-hit theory
(Hermanowicz, 2015), genome theory, Darwinian theory of social change (Richerson &
Boyd, 2000), and the multi-level biologic, social integrative construct (MBASIC). The
theoretical cocktail of UPCC could interlock new insights on tumor initiation, metastases
diagnostic, and treatment strategies.

Figure 1. Component cause model for the causes of hypothetical pathopoiesis mechanism
of smoking and family cancer history in the etiopathogenesis of pancreatic cancer.
The germ theory of disease of the 20th century needs to be in the context of 21st
century medicine (Whitcomb, 2014) and part of a metatheory that will classify patients
based on a risk factor or a combination of factors (e.g., smoking, gender, age) that could
contribute to the existing knowledge of PC etiology rather than its symptoms and
complications. Although traditional evolutionary theory could help the understanding of
pancreatic tumor growth at the molecular level (Aktipis, Boddy, Gatenby, Brown, &
Maley, 2013), the genome theory of cancer evolution (Vogelstein et al., 2013) could help
explain the direction of development and pattern of progression of the disease. Cancer of
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the pancreas is a genetic disease, and MBASIC could help explain its Darwinian
character and link the correlation of tobacco use and family cancer history. According to
Lynch and Rebbeck (2013), MBASIC allows researchers from the fields of public health,
health policy, epidemiology, biology, clinical medicine, prevention, behavioral sciences,
sociology, and others to test hypotheses of interest. MBASIC aided in the study design,
guided the development of statistical or mechanistic models to examine the covariates,
and positioned the results of this study for improved intervention, translation, and
implementation.
Nature of the Study
Assessment of lifetime smoking history selected through random stratification
from the core sections and cancer survivorship module of the 2014 BRFSS data sets was
not only a valuable instrument for this study but also for the future development of the
Expanded BRFSS. The key variables in this dissertation were cancer types from the
BRFSS cancer survivorship module (outcome), and the core section on tobacco use,
gender, and age (predictors). The intent of this study was to examine the association
between smoking, gender, age, PC, and shared genes. Popular study designs are subject
to various biases that include social desirability, recall, and selection bias. Despite the
weaknesses of secondary data and cross-sectional studies, multiple outcomes and
exposures can be explored using a cross-sectional design.
The argument on the influence of tobacco consumption on individuals with shared
genes and calculating prevalence proportion, the positive and negative predictive values
of the regression models were assessed to determine the statistical significance of the
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independent variables (smoking status, gender, age) in the induction and progression of
PC. The ordinal logistic model was used to consider possible correlation. Secondary data
from the 2014 BRFSS were recoded and randomized using the Statistical Package for the
Social Sciences (SPSS).
Definitions
BRCA2: BReast CAncer Gene 2, the tumor suppressor gene associated with
hereditary predisposition to pancreatic, breast, ovarian, and other cancers (Cassidy, Liau
& Venkitaraman, 2014).
Clonal mutation: A mutation that exists in the vast majority of neoplastic cells
within a tumor (Vogelstein et al., 2013).
Darwinian model: A theory used to explain that the genetic variation introduced
continually into the population via stochastic mutational events and that those cell clones
that happen to acquire alleles conferring proliferative and/or survival advantages become
overrepresented via a process of purifying selection (Valastyan & Weinberg, 2011).
De novo: An alteration/mutation in a gene that is present for the first time in one
family member as a result of a mutation in a germ cell of one of the parents or in the
fertilized egg itself (Pagon et al., 2016).
Driver gene: A gene that contains driver gene mutations (Mut-Driver gene)
expressed aberrantly in a fashion that confers a selective growth advantage (Epi-Driver
gene).
Epigenetic: Denoting processes by which heritable modifications in gene function
occur without a change in the sequence of the DNA (Spraycar, 1995).
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Etiopathogenesis: A portmanteau of etiopathology and genesis; the cause and
development of a disease or abnormal condition (Merriam-Webster, n.d.).
Family cancer history (FCH): Familial pancreatic cancer referred to in this study
simply as family cancer history (FCH), cancer predisposition genes (CPG), or shared
genes—elaborating on the known genetic syndromes (Rustgi, 2014), and germline
mutations such as BRCA2 (Grant et al., 2015).
Gene-environment interaction: In genetic epidemiology, genetic factors that
confer susceptibility or resistance to pancreatic cancer in a particular environment
(Khoury, Davis, Gwinn, Lindegren, & Yoon, 2005; Willett, 2002).
Genetic heterogeneity: The character of a phenotype produced by diverse
mechanisms that can be distinguished by special methods such as linkage analysis but are
ordinarily indistinguishable.
Genetic polymorphism: The occurrence in the same population of two or more
alleles at one locus, each with appreciable frequency (Cavalli-Sforza & Bodmer, 1971).
Genome theory: A model used to guide the understanding of timing occurrence of
genetic events in pancreatic carcinogenesis and progression (Makohon-Moore et al.,
2013).
Germline genome: An individual’s genome as inherited from his or her parents
(Vogelstein et al., 2013).
Germ theory of disease: In the context of the 21st century, a framework in which
the number of variants resulting in disease equals one (Whitcomb, 2014).
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Inherited cancer predisposition: A means to identify genes that may have
significant normal roles in the control of growth and differentiation, and which when
faulty can predispose to malignancy (Ponder, 1991).
KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog): One of a class of
genes known as oncogenes, which when mutated have the potential to cause normal cells
to become cancerous (Kranenburg, 2005).
Latency period: The delay between a cause and its effect, or the time between
causal factors and diagnosis (Spraycar, 1995).
Metatheory: The integration of various theories (Anchin, 2008; Ritzer, 1988).
Multilevel biologic and social integrative construct (MBASIC): A model that
guides transdisciplinary collaborations to maximize the value of multilevel studies for
clinical and public health activities, and to integrate macro environment and individual
factors with biology (Lynch & Rebbeck, 2013).
National familial pancreas tumor registry (NFPTR): A research registry
established at Johns Hopkins University in 1994 (Shi, Hruban, & Klein, 2009).
PALB2 (Partner and Localizer of BRCA2): A pancreatic cancer susceptibility
gene; PALB2 mutations occur in patients with familial pancreatic cancer (Jones et al.,
2009).
Pancreatic cancer (PC): The predominant histologic type of cancer in sporadic
and familial cancer of the pancreas estimated to become the second leading cause of
cancer death in the United States by 2020 (Rahib et al., 2014).
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Pancreatic ductal adenocarcinoma (PDAC): Referred in this study as pancreatic
cancer (PC), representing the fourth leading cause of cancer mortality worldwide, with an
incidence of approximately 217,000 new cases each year nearly matched by 213,000
deaths (Parkin, Bray, & Devesa, 2001).
Pathometry: The determination of the proportionate number of individuals
affected with a certain disease at a given time, and of the conditions leading to an
increase or decrease in number (Stedman, 2012).
Pathopoiesis: The tendency of an individual to become ill; the mode of
production of disease.
Postmodernism: A reaction to the assumed certainty of scientific or objective
efforts to explain reality (Stringer, 2014).
Subclonal mutation: A mutation that exists in only a subset of the neoplastic cells
within a tumor (Vogelstein et al., 2013).
Susceptibility gene: A gene mutation that increases an individual’s susceptibility
or predisposition to a particular disease or disorder.
Tobacco use: A modifiable risk factor associated consistently with a twofold
increased PC risk (Jansen et al., 2015).
Traditional evolutionary theory: A model explaining evolutionary processes that
drive cancer progression; the model helps in understanding tumor growth dynamics to
narrow the search for specific mutations that drive different aspects of the disease
(Rodriguez-Brenes, Komarova, & Wodarz, 2013).
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Tumor suppressor gene: A gene that when inactivated by mutation increases the
selective growth advantage of the cell in which it resides (Vogelstein et al., 2013).
Assumptions, Limitations, Scope, and Delimitations
Assumptions
By the year 2020, PC is estimated to become the second leading cause of cancer
death in the United States (Chari et al., 2015). Tobacco use may be not only a cancercausing agent but also a lifestyle-related factor associated with the etiopathogenesis of the
disease. Familial pancreatic cancer is thought to be genetically heterogeneous (Zhen et
al., 2015), and other inherited mutations are referred in this dissertation as FCH or CPG.
All calculations were conducted under the assumption of the association of smoking,
gender, and age to individuals with FCH, or the synergism of these factors in the
initiation of pancreatic cancer. Yes/no P16(CDKN2A), PRSS1, BRCA1, STK11/LKB
genes among participants with FCH, or smoking history as the binary outcome, was
explored in correlation with the disease prevalence. The probability of developing
pancreatic cancer is virtually impossible to tell. Therefore, it is important to examine the
pathopoiesis mechanism of smoking as a lifestyle-related factor or modifiable risk factor
in correlation with gender, age, and CPG in the development and progression of
pancreatic cancer.
Scope and Delimitations
The occurrence of PC/CTS-GA under the defined combined role of risk factors in
this dissertation was sparse or rarely discussed in previous research. Hassan et al. (2007)
asserted the need for further assessment of the synergistic interaction between smoking
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and diabetes, and positive family history of pancreatic cancer in other large-scale
epidemiological studies of different populations, in men and women separately. Gender
and age were included in the statistical analysis to establish connections at a single point
in time, in addition to smoking lifetime history or its combined role in the prevalence of
PC and CTSG-A, statistical adjustment through age post-stratification (<51, 52-69, 70>)
to weight for probable selection bias. Reported age of onset for familial pancreatic cancer
(FPC) collated from previous investigations was 52-69 years (Norris et al., 2015). In the
current study, gender, race/ethnicity, and age were considered for statistical analysis to
assess differences in induction and promotion of PC.
The sampling frame of this study included randomly selected data from the 2014
BRFSS. To achieve generalization, G*Power was used to establish sample size. If the
suggested sample size failed the ordinal logistic regression assumptions, the remaining
sample after data cleaning was used. Producing well-grounded evidence would contribute
to the mission of the source of the secondary data. Emphasizing the impact of modifiable
or lifestyle risk factors such as smoking in the induction and promotion of PC may
promote not only positive social change but also future studies in establishing a national
or international consortium for PC to develop a risk model for early detection of the
disease (Hassan et al., 2007).
Limitations
Given the time involved and other challenges in establishing institutional
collaboration between Walden University and the Johns Hopkins University National
Familial Pancreas Tumor Registry (NFPTR), the 2014 BRFSS data sets were used in this
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study. Limitations of secondary data include missing data and reusing existing data sets
from previous studies. Although it was important to be aware of ethical issues and
weaknesses of using secondary data, following the minimum standards of preparing the
2014 BRFSS Module for analysis was critical to the quality of this study.
Significance of the Study
By the year 2030, it is projected that PC will be the second leading cause of
cancer death after lung cancer among the major types of cancer (Rahib et al. 2014). The
outcome of this study would provide valuable insights into the etiopathogenesis of PC
and CTS-GA, as well as the possible recognition of the probable unique pattern of PC
malignancy among defined age groups, between men and women, in correlation to the
modification effect of smoking to CPG, or its combined impact. Additional
understanding of the pathopoiesis dynamics of smoking status, gender, and age in
individuals with CPG in the induction and promotion of PC could help promote pre- and
post behavioral diagnosis change. This study may assist in developing a novel patient
management approach to accurately assess the disease burden under the lens of public
health and modern epidemiology.
Variability of previous exposures and cumulative effects of smoking, and
prevalence patterns among defined age groups between men and women in association
with individuals with CPG versus nonsmokers with CPG could explain the difference in
latency periods and degrees of pancreatic cancer progression. Exploring the combined
arbitrary role of smoking and CPG in the progression of PC may confirm the importance
of addressing the need for fostering behavioral change by adopting healthy habits among
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high-risk individuals. Moreover, this study could provide further insights into behavior,
prevention, and mechanisms associated with PC risk. Although the procarcinogenic
effects of tobacco use on the pancreas are inadequately studied (Pandol et al., 2012),
closing the gap in knowledge continuity in the understanding of PC epidemiology
regarding the association between smoking and shared genes that could impose comorbid
conditions was critical to the advancement of efficient clinical practice. The focus of
most research in PC epidemiology is on the improved understanding of risk factors in
association with clinical treatment to alter the expression or final stage of the disease.
Following the blueprint of public health intervention, this study focused on understanding
the interaction between biologic, individual, and microenvironmental factors in the
induction and promotion of PC. The outcome of this study may justify the importance of
behavioral change.
Positive Social Change Emerging from the Study
The commonality of modernism and 21st century thinking (postmodernism) is the
goal of living the highest quality of life. The greatest challenge of this study was to
improve the outcome of those diagnosed with PC and CTSG-A known to have increased
risk of extrapancreatic malignancies. Patients diagnosed with PC have a poor prognosis
of 28% 1-year survival rate, and 4-7% 5-year survival rate (American Cancer Society,
2015). The only way to stop the fear after being diagnosed with PC is by managing
emotional issues and social concerns. People may sometimes struggle with changes in
their social roles or situation, but high-risk individuals have a choice to make lifestyle
changes. The 21st century thinking underscores the noteworthiness of making healthy
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lifestyle changes that affect not only the risk of developing the disease but also the ability
to function independently in later life. The 21st century approach to advancing the vision
for prevention requires innovative steps on integration and a comprehensive way of
promoting public health. Part of creative actions is accepting the significance of social
change in the sphere of enhanced quality of life. Focusing on the impact of cigarette
smoking as a modifiable risk factor that promotes PC and CTSG-A rather than initiates it
may amplify the importance of behavioral change promoted through health care policy
changes. According to a report on recommendations of the Task Force on Community
Preventive Services (2000), assessment of current tobacco-use prevention and cessation
activities is paramount in the development of a comprehensive strategy to reduce
initiation, increase cessation, and reduce exposure to environmental tobacco smoke.
Parallel to this recommendation, Bunnell et al. (2012) stated that future work to combat
interrelated economic and health challenges could build on the Communities Putting
Prevention to Work (CPPW) approach. Beneﬁts from the strategic selection of priorities,
robust support for individual community needs, and enhanced accountability to ensure
ﬁdelity to the design of program plans (Bunnell et al., 2012) may improve the CPPW
approach in implementing evidence-based tobacco-use interventions.
Summary
In this chapter, I addressed smoking as the strongest avoidable risk factor for PC
and CTSG-A along with other predictors (age, gender) emphasizing the intent of this
study was not only to explore its likely modification effect among individuals with CPG
but also to highlight the positive social change through smoking cessation. Moreover, the
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call for further research on the procarcinogenic effects of smoking (Pandol et al., 2012)
was acknowledged. Conceding the need to investigate the genetic and environmental
interactions associated with the increased PC risk (Schenk et al., 2001) affirmed the
significance of the development of prevention and control strategies and lifestyle changes
to reduce cancer risk. Exploring predictors’ association with CPG may contribute to the
understanding of pancreatic carcinogenesis, critical to the advancement of efficient
clinical practice.
The outcome of this study may provide valuable information to future researchers
improving current understanding of genomic instability, one of the leading causes of
genetic heterogeneity (Burrell et al., 2013). Previous studies indicated that this disease
has a complex genomic landscape (Campbell et al., 2010). It was therefore critical to
explore the extent of the current understanding of PC, to recognize the probable effect
modification of smoking, and to examine the correlation of gender and age to disease
initiation and progression among individuals with CPG. Chapter 2 provides an in-depth
review of the literature addressing the cancer genome landscape, patterns, dynamics of
genomic instability in PC evolution, and the etiopathogenic role of tobacco use. The
accumulation of mutations in a variety of genes is discussed, antecedent to the
procarcinogenic effects of smoking, making the disease a highly malignant tumor with
few viable therapeutic options (Makohon-Moore et al., 2013).
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Chapter 2: Literature Review
The early symptoms of pancreatic cancer (PC) often mimic other benign
conditions, and its biological complexity adds challenge to early detection, resulting in a
highly malignant tumor with few viable treatment options. The evolution of PC
progression involves its genetics from initiation to the tumor’s ability to adapt and grow
even with intense therapy. The primary reasons for its poor clinical resistance are early
metastasis, chemoresistance, and late clinical outcomes. Asymptomatic in the early
stages, PC is a highly lethal cancer difficult to detect with a median survival of less than
6 months, and a 5-year survival rate of less than 5% (Klein, 2012). According to Yachida
et al. (2010), it takes at least 15 years from the time of the initiating mutation to
metastasis, making the tumor unresectable and aggressive in a metastatic state by the time
PC is diagnosed. Vital to the development of therapies, mapping of the PC genome that
target many genetic abnormalities will aid in the understanding of pancreatic
carcinogenesis, crucial in improving clinical outcomes.
The mechanisms through which smoking, gender, age, and cancer predisposition
genes (CPG) affect PC remain unknown, making it critical to explore the role of these
three predictors in the disease clustering to develop a more efficient management and
clinical approach. With an exhaustive understanding of the patterns of somatic alteration
in pancreatic carcinogenesis comes the opportunity to understand the influence of these
factors on metastatic progression (Yachida & Iacobuzio-Donahue, 2013). Working
toward this goal, the key intent of this dissertation was to highlight the pathopoiesis

25
mechanism of tobacco use and CPG, as well as the etiopathogenic role of gender and age.
New research directions are warranted to reverse the lethal outcome of this disease.
In this chapter, I provide a scholarly review of literature related to the current
state of understanding of PC. I searched for peer-reviewed studies on PC using the
Thoreau database with a restriction on the year of publication from 2011 to 2016.
Scholarly literature published before 2011 was considered to establish a historical
perspective on the progression of pancreatic carcinogenesis research. Bookends On Tap,
a reference management iPAD app, provided current articles across databases including
PubMed, PubMed Central, Google Philomath, JSTOR, and arXiv. Using Evernote and
Microsoft OneDrive, I conducted an automated search weekly to identify current
literature using the myNCBI feature of PubMed. Blogs, non-peer-reviewed papers, and
forum posts were omitted to ensure that references were of high quality.
Background
In the United States, smoking-related illness costs more than $300 billion each
year (Warren, Alberg, Kraft, & Cummings, 2014), and since the 1970s tobacco use
remains a major risk factor of PC. According to Pandol et al. (2012), accumulating
evidence has indicated that carcinogenic compounds from tobacco use stimulate
pancreatic cancer progression. Pandol et al. noted the economic burden of PC with an
expected yearly cost of $4.9 billion and underscored the significance of determining the
mechanisms underlying the effect of smoking compounds that may provide additional
insights into the pathogenesis of the disease. The investigation gave valuable insights into
the etiopathogenesis of pancreatic growth from its induction and promotion.
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The present understanding and the surge of awareness of PC in the 21st century
began with the significant progress achieved by the discovery of the human pancreatic
duct in 1642 by Wirsüng, followed by Blobel’s discovery of signaling mechanisms that
govern the transport and localization of proteins within pancreatic acinar cells in 1999
(Ceranowicz, Cieszkowski, Warzecha, Kuśnierz-Cabala, & Dembiński, 2015). At
present, solid tumors are interpreted as alterations in driver genes (Armitage & Doll,
1954; Vogelstein et al., 2013) that ordinarily require five to eight hits in classic
epidemiologic studies. According to Vogelstein et al. (2013), several tumors have only
one or two driver gene mutations, as shown in Figure 2. Given that cancer genome
sequencing is a relatively new endeavor, the identification of three oncogene mutations
and six alterations with both oncogene and tumor suppressor gene mutations in PC will
give way to the most appropriate management plan (Vogelstein et al., 2013).
The outcome of cancer genome sequencing already had an impact on the clinical
care of cancer patients. However, a greater emphasis on probabilistic thinking and
clinician numeracy are essential in the development of new models for creating an
efficient medical care system centered on the quality of care, extending and improving
the quality of life for patients diagnosed with PC and CTSG-A. There is a need to
integrate epigenetics, proteomics, and metabolomics in the analysis of genomic data, and
the addition of a sophisticated clinical workforce (Krier & Green, 2013) will contribute to
the management of incidental findings. Additionally, given the significant environmental
factors’ role in the etiology of sporadic pancreatic cancer (Raimondi, Maisonneuve, &
Lowenfels, 2009), it is necessary to develop diagnostic tests that not only aid in the
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identification of susceptible individuals or monitor disease progression, but also aid in
prevention or guide PC treatment (Hocevar et al. 2014).

Figure 2. The number and distribution of driver gene mutations in pancreatic cancer
compared to other tumor types (Vogelstein et al., 2013, p. 29).
Pancreatic Cancer Genetic Landscape and Molecular Biology
Subject to evolutionary paradigms, PC emerged as a disease of inherited and
somatic mutations from more than two decades of research (Maitra & Hruban, 2008).
Sequencing of the germline of individuals with a strong family history of pancreatic
cancer and those with a genetic predisposition to the disease is critical to raising
awareness of the promise of extrapancreatic neoplasm screening in identifying early
curable pancreatic neoplasia (Iacobuzio-Donahue, Velculescu, Wolfgang, & Hruban,
2012). There are three important points to remember about the germline genetic
syndromes (GGSs) associated with lifetime PC risk. First, quantifying PC risk of known
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genes responsible for the aggregation of PC in a family is necessary for the design of
clinical trials of at-risk patients screening for early curable precancerous lesions (Canto et
al., 2012; Canto et al., 2013). Second, both high and low-penetrance genes except genes
associated with familial pancreatitis increase the PC risk and extrapancreatic
malignancies. Lastly, although screening for extrapancreatic malignancies can save lives,
it is important to remember that some of these GGSs have implications for therapy. The
changes in the clinical management of neoplasms with somatic mutations begotten by the
sequencing of the most common types of pancreatic tumors warrant the search for new
strategies in the early detection and treatment of pancreatic neoplasia (Wolfgang et al.,
2013).
Endocrine and exocrine pancreatic tumor genetics and biology can be profoundly
influenced by the particular type of origin, exhibiting considerable divergence in their
mutational spectra and clinical behavior (Jiao et al., 2011). With regard to the evidence
for clonal diversity between primary and metastatic sites, Campbell et al. (2010) found
the amplification of cancer genes predominantly occurring in early cancer development
and genetic heterogeneity among metastasis-initiating cells. The data presented in this
study confirmed the richness of genetic variation in cancer. Like Campbell et al. (2010),
Waddell et al. (2015) also discussed the genomic instability concerning cancer
dissemination and metastases. In addition to numerous genes mutation at low prevalence,
Waddell et al. substantiated the importance of V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS), Tumor protein p53 (TP53), SMAD Family Member 4
(SMAD4), cyclin-dependent kinase Inhibitor 2A (CDKN2A), and AT-Rich Interaction
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Domain 1A (ARID1A) gene mutations. Waddell et al. found the role of chromatin
modification and the broader role for aberrant Wnt signaling pathway (KW-0879) in
recurrent mutations identified in Lysine Demethylase 6A (KDM6A). Waddell et al.
provided the most comprehensive description of the genomic events that characterized
pancreatic cancer and demonstrated the prominent structural variation mechanism of
genomic damage in this disease.
Worldwide, 85% of PC cases are adenocarcinomas, and 1 to 10 cases per 100,000
have the incidence of all types of PC. According to Ryan, Hong, and Bardeesy (2014),
PC has ranked as the eighth leading cause of death among men, and the ninth leading
cause of death among women globally for the past 30 years. Like Blackford et al. (2009),
Ryan et al. found the role of KRAS mutations in the etiopathogenesis of the disease.
Given the risk factors and established genetic syndromes associated with the condition
(see Table 1), and despite the unidentified genetic basis of familial aggregation, Ryan et
al. agreed with Klein et al. (2004) that PC has the estimated 5 to 10% unidentified
inherited component in familial aggregation. Somatic structural rearrangement of
chromosomes as part of the mutational landscape of PC could lead to the development of
novel screening, surveillance, and therapeutic strategies.
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Table 1
Risk Factors and Inherited Syndromes Associated With Pancreatic Cancer
Variable

Approximate risk

Risk factor
Smoking (Bosetti et al., 2012)

2-3

Long-standing diabetes mellitus (Ben et al., 2011)

2

Nonhereditary and chronic pancreatitis (Duell et al., 2012)

2-6

Obesity, inactivity, or both (Aune et al., 2011)

2

Non–O blood group (Klein et al., 2013)

1-2

Genetic syndrome and associated gene or genes— %
Hereditary pancreatitis—PRSS1, SPINK1 (Rebours et al., 2008)

50

Familial atypical multiple mole and melanoma syndrome—p16
(Vasen et al., 2000)

10-20

Hereditary breast and ovarian cancer syndromes—BRCA1, BRCA2,
PALB2 (Iqbal et al., 2012; Jones et al., 2009)

1-2

Peutz–Jeghers syndrome—STK11 [LKB1] (Giardiello et al., 2000)

30-40

Hereditary nonpolyposis colon cancer (Lynch syndrome)—MLH1,
MSH2, MSH6 (Kastrinos et al., 2009)

4

Ataxia–telangiectasia—ATM (Swift et al., 1991)

UNKN

Li–Fraumeni syndrome—P53 (Ruijs et al., 2010)

UNKN

Note. Adapted from “Pancreatic Adenocarcinoma” by D.P. Ryan, T.S. Hong, and N.
Bardeesy, 2014, New England Journal of Medicine, 371(11), p.1040. Copyright 2014
Massachusetts Medical Society. UNKN = Unknown.
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To date, surgical resection remains the only potentially curative treatment
according to Zakharova et al. (2012), albeit only 15%-20% of patients with PC are good
candidates for the procedure. On the other hand, the focus of health care providers on
prolonging life, helping patients and their family through difficult transitions after
diagnosis are equally as important as improving survival through the development of
optimal treatment algorithm (Wolfgang et al.,2013). The increased use of high-quality
multi-detector computed tomography (MDCT), neoadjuvant treatment with systemic
chemotherapy, and the enormous strides in exploring the underlying genetics of
pancreatic cancer are critical parts of an individualized treatment algorithm
(Varadhachary et al., 2006; Zakharova et al., 2012). The outcome of this dissertation in
combination with such an innovative, evidence-based treatment plan could improve
perioperative care and quality of life.
The particular application of past and current research on inherited mutations to
this dissertation supports an earlier study by Tersmette et al. (2001) that demonstrated the
risk of developing PC among first-degree relatives (FDRs) in the family with the disease.
In this study, the researchers found that PC kindreds with three or more affected relatives
show a 57-fold (95% CI = 12.4–175) increased the risk of pancreatic cancer. Tersmette et
al. (2001) stated that although the gene or genes responsible for familial PC have not yet
been identified, the findings highlighted the importance of the development new PC
chemoprevention and screening modalities that will benefit this group of individuals (p.
733). Following this point of inquiry, Ludwig et al. (2011) delve into the rationale for
strategies in identifying early detection of precursor lesions or early cancers in high-risk
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groups that could improve disease-specific outcome. The researchers perused the
significant yield of screening at-risk relatives of familial pancreatic cancer patients.
Magnetic resonance cholangiopancreatogram (MRCP) was used to screen 309
asymptomatic at-risk relatives enrolled in the Familial Pancreatic Tumor Registry (FPTR)
of Memorial-Sloan Kettering Cancer Center (MSKCC) to validate the results of prior
studies as to the safety and efficiency of MRCP as an initial screening modality. If
indicated, endoscopic ultrasound with fine needle aspiration was performed. MRCP
produced a significant diagnostic yield, particularly in family members >65 years of age.
Akin to the objective of the study of Ludwig et al. (2011), an earlier investigation
by Klein et al. (2004) examined the significance of familial PC history (FPCH) as a
rational basis for cancer risk screening and counseling. In this prospective registry-based
study, using the National Familial Pancreas Tumor Registry (NFPTR) as a resource of
familial pancreatic cancer (FPC), Klein et al. contrived the probable denotative increased
risk of pancreatic cancer in FPC kindreds. The quantification of family members
diagnosed with the disease supported the hypothesis of increased risk among individuals
with FCH. The study found an increased PC risk with burgeoning numbers incidence
among FDRs. Parallel to this rationale, several studies asserted a two to a five-fold excess
of pancreatic cancer in FDRs of patients with PC, augmented among smoking relatives of
patients with the disease (Brentnall et al., 1999; Schenk et al., 2001). The prospective,
registry-based study of Klein et al. (2004) help quantified the risk of pancreatic cancer in
kindreds in which a family member has received a diagnosis of PC (p.2637). The findings
added to the body of evidence that the familial aggregation of pancreatic cancer is often
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not due to chance, and demonstrated that a strong family history of PC significantly
increases the risk of PC development.
Complex Darwinian Evolutionary System
Parallel to the Darwinian natural selection, Peter Nowell’s landmark perspective
on cancer as an evolutionary process is driven by stepwise, somatic cell mutations with
sequential, subclonal selection (Nowell, 1976). Considered as a legitimate scientific
theory, the evolutionary theory of cancer has survived 35 years of empirical observation
and testing (Greaves & Maley, 2012). Whereas the understanding of the essential
components of somatic evolution is well established, Greaves and Maley (2012) noted
the tools from evolutionary biology that may be applied to neoplasms to give light on the
uncertain disposition on the dynamics of somatic evolution and address the fundamental
questions in cancer biology. The diverse mutational processes involved in carcinogenesis,
modern cancer biology, and genomics validated cancer as a complex, Darwinian,
adaptive system (Merlo et al., 2006; Greaves & Maley, 2012). Using a non-spatial
population genetics model of sequential, exponential clonal expansion, Bozic et al.
(2010) formulated an equation to pancreatic cancer resequencing data in estimating driver
mutation. The empirical evidence established by tumor biology and genetics on the
considerable divergence in the mutational spectra and clinical behavior of endocrine and
exocrine PCs emphasized the need to advance genomics technologies (Jiao et al., 2011).
Furthermore, Jiao et al. (2011) noted that making improvements on genomics
technologies will heighten the understanding of how genomic instability shapes tumor
evolution. While genomic instability may be an attractive therapeutic target; such
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weakness can leave distinct genomic footprints through various routes, affecting tumor
development and patient outcomes (Burrell et al., 2013).
The genetic complexity of PC, hampers the progress in the identification of novel
therapies, making the early diagnosis of the disease as one of the few options for
improved outcomes (Hidalgo et. al, 2015). Such complexity made the dynamics of clonal
diversification and selection in the foreground to understand neoplastic progression and
response to therapy. According to Greaves and Maley (2012), the control, delay or
prevention of cancer mortality is dependent upon the clinical opportunities to address
evolutionary adaptability of neoplasms. Applying the evolutionary clock model to the
number of mutations that have been quantified in tumors representing progressive stages
of PCs lead to two definite conclusions (Jones et al., 2008; Yachida et al., 2010;
Vogelstein et al., 2013). First, a full-blown, metastatic cancer takes decades to develop,
and mutations are already virtually present in a significant number of cells in the primary
tumors (Vogelstein et al., 2013). Second, the timing of mutations verbalized in this study
is relevant to our understanding of metastasis (Vogelstein et al., 2013), fortifying the
desideratum for the development of new screening modalities that will justify preventive
surgical intervention.
The new insights into the biology and genetics of PC, recognizing CDKN2A (G1
cell cycle arrest pathway) and p53 (p53 pathway) argued by Ryan et al. (2014) as the
commonly mutated oncogenes in this study, in addition to new findings regarding KRAS
mutations, tumor metabolism, and tumor immunology, may be of value in the
development of new treatments. In addition to discoveries regarding KRAS mutations,
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tumor metabolism, and tumor immunology, Ryan et al. (2014) emphasized the
importance of new insights into the biology and genetics of pancreatic cancer, essential
elements in the development of new treatments. Given the paucity of documented
presence of branched evolution and clonal diversity between primary and metastatic sites
in pancreatic tumor development (Campbell et al., 2010; Yachida et al., 2010), cancer
genomes can be exploited for elaborating the need for developing more effective
immunotherapies (Vogelstein et al., 2013).
The Whole-genome and Whole-exome data analyzed in the 2013 study of
Lawrence et al. suggest a strong correlation between somatic mutation frequency in
cancers and gene expression level. Lawrence et al. (2013) focused on two dominant
factors that explain mutational heterogeneity: the gene expression level where the
germline mutation rate affected by transcription-coupled repair, and replication time of a
DNA (deoxyribonucleic acid) region during the cell cycle (Fousteri et al., 2008;
Pleasance et al., 2010). Based on the analysis of the massive amounts of whole-genome
sequencing, Lawrence et al. (2013) concluded that the accurate accounting of mutational
processes is dependent upon the precise identification of new cancer genes. Relevant to
the discussion of mutational processes, it would be beneficial to note the association of
the familial clustering of PC with several features of the genetic syndromes. Individuals
with a strong family history of PC with a first-degree relative with the disease have a 2.3fold increased risk of developing the malignancy (Amundadottir et al., 2004). The
increased risk that could be explained by an autosomal dominant inheritance of a rare
allele (Klein et al., 2004); Maitra and Hruban (2008) noted that the association of the
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disease with some germ-line genetic alterations could provide insights into its
pathogenesis. While the absence of a strong family history of cancer cannot be used to
rule out a germline mutation, according to Maitra and Hruban (2008) shown in Table 2—
most of the germline mutations except those in the Protease, Serine 1 (PRSS1) gene are
associated with an increased risk of extrapancreatic malignancies.
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Table 2
Germline Mutation Genes
Individual

Gene

Relative risk
1

Risk by
age 70
0.5%

Cancer
morphology
NS

No history

None

Breast
Cancer

BRCA2

3.5-10x

5%

NS

BRCA1

2x

1%

P16
(CDKN2
A)
UNKN

20-34x

10%17%

Breast cancer
with basaloid
features
NS

32x

16%

NS

UNKN

PRSS1

50-80x

25%40%

None

Lowenfels et al.,
1997

PeutzJeghers

STK11/L
KB1

132x

30%60%

Pancreatic
cancers in the
background
of severe
diffuse
chronic
pancreatitis
NS

Su et al., 1999;
Giardiello et al.,
2000

HNPCC

bMLH1,
bMSH2,
others

UNKN

< 5%

Medullary
and colloid
phenotypes

Young-ageonset
pancreatic
cancer

FANC-C
and
FANC-G

UNKN

UNKN

NS

Gastroesop
hageal,
small
bowel,
colorectal,
breast
Colorectal,
endometria
l, stomach,
ovarian,
ureter and
renal,
pelvis,
biliary
tract, brain
UNKN

FAMMM

Familial
pancreatic
cancer (3
FDR)
Familial
pancreatitis

Other
cancers
None

Breast,
Ovary,
Prostate
Melanoma

Reference(s)

Goggins et al.,
1996; Ozçelik et
al., 1997
Lynch et al., 2005

Bartsch et al.,
2002; Parker et
al., 2003
Klein et al., 2004

Goggins et al.,
1998;
Yamamoto et al.,
2001

Van der Heijden
et al., 2003;
Couch et al., 2005
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Note: Genes associated with an increased risk of pancreatic cancer: 3 FDR, 3 or more
first-degree relatives with PC; FAMMM, familial atypical multiple mole melanoma
syndrome; HNPCC, hereditary non-polyposis colorectal cancer syndrome; NS, nonspecific. UNKN = Unknown.
From an Evolutionary Model to the Unified Paradigm of Cancer Causation (UPCC)
Three important events launched the field of cancer epidemiology during the 18th
century. First, is Bernardino Ramazzini’s study on cervical cancer in 1713, the research
of Percival Pott in 1775 that led the way on occupational carcinogenic exposure studies,
and Thomas Venner on the danger of tobacco use in his Via Recta, published in London
in 1620 (American Cancer Society, 2014). After two centuries when John Hill wrote a
book entitled “Cautions Against the Immoderate Use of Snuff” in 1761; Krain (1970),
along with other studies in the 1970s, Wynder, Mabuchi, Maruchi and Fortner (1973)
explored the causality of tobacco use in the development of PC. Jones et al. (2008) found
that PCs have an average of 63 genetic alterations that can explain the major features of
pancreatic tumorigenesis. The intensive genetic studies described by Jones et al. (2008)
gave way to the better understanding of the core set of pathways and processes,
embracing the idea of Owens, Coffey, and Baylin (1982) that tumor heterogeneity is a
fundamental facet of all solid tumors. While PC has few viable treatment options, Jones
et al. (2008) suggested that the best hope for therapeutic development may lie in the
discovery of agents that target the physiologic effects of the altered pathways and
processes rather than their gene components. Above all, the significance that could not
have been appreciated in the absence of global analysis is the identification of the precise
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genetic alterations that may be responsible for tumor pathway dysregulation (Jones et al.,
2008).
The pathogenic theory of medicine or the germ theory of disease was highly
controversial when first proposed as a concept that microorganisms are the cause of many
diseases. After validation in the 19th century, germ theory revolutionized both medical
thought and the art of surgery, becoming a fundamental part of modern medicine and
clinical microbiology. The UPCC, a metatheory in this dissertation as a composite of
germ theory and Darwinian evolutionary system (Greaves & Maley, 2012) along with
other theories mentioned in the previous chapter will provide clarity on the narrative of
the initiation of PC. Albeit the acceptance of the somatic mutation theory of
carcinogenesis (SMT) as the mainstream narrative of how neoplasms develop (Soto &
Sonnenschein, 2004), SMT included in the UPCC’s cocktail of theories will build on the
arguments of the core principle of genetic variation and pattern of mutations
(environmental and genetics) that are sufficient probable causes of the disease. In this
chapter, UPCC will explain the behavior of PC cell in rationalizing the complex array of
the possible interaction of smoking and inherited genes.
Pancreatic cancer is the fourth commonest cause of cancer death in Western
societies and is projected to be the second leading cause within a decade (Waddell et al.,
2015). As a consequence, this dissertation will address the urgent need to follow through
in the assessment of EGBIs and fill the gap of prior studies of not considering the
reasonable modification of environmental exposures (smoking) to the genomic landscape
of the disease. While using the Darwinian methods links human sociocultural progress to
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genetic evolution (Richerson & Boyd, 2000); Lynch and Rebbeck (2013) used a “Multilevel Biologic and Social Integrative Construct” (MBASIC) to integrate macro
environment and individual factors with biology. Considering the limitation and
information generated by single-level studies have reached a saturation point (Lynch &
Rebbeck, 2013), this dissertation acknowledges the significance of individual level
(behaviors, carcinogenic exposures); and biologic level (inherited susceptibility variants).
Germline changes associated with PC (see Appendix) could range from slightly increased
risk (low penetrance genes) to high lifetime risk (high penetrance genes). Given that PC
is the antecedent of inherited (germline), and acquired (somatic) mutations in cancercausing genes, adding the probable correlation between gender and age, modifying effect
of smoking to the equation that could trigger or wake up a sleeping germline mutation
could position the result of this dissertation for improved public health intervention,
translation and implementation in clinical settings to alter the expression of the disease.
Smoking: A Modifiable Behavioral Risk Factor
Tobacco smoking is recognized as a significant environmental factor and the
strongest avoidable risk factor, and Pandol et al. (2012) highlighted the need for further
research on its procarcinogenic effects. The gap of this 2012 study was explored by
Schulte et al. (2014), and the researchers comprehensively discussed the tobacco
component primarily relevant to pancreatic cancer risk (PCR). Regression models were
employed in this study generating statistical results broadly consistent with the
association of both smoking intensity and smoking duration to PCR. The conclusion
justified the role of smoking pattern in the greater risk of developing the disease. While
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Pandol et al. (2012) and Schulte et al. (2014) are closely akin in investigating the
association between cigarette smoking and PC, the outcome of the study of Schulte et al.
(2014) complements the findings of Blackford et al. (2009) on DNA damage as the
antecedent of tobacco carcinogens. Whereas the study confirmed an increased mutation
trends among smokers, in contrast to previous research, the researchers did not observe
an association between KRAS gene mutations and tobacco use. KRAS is one of the
molecular switches in signal transduction and one of the genes belonging to the Ras gene
family. Malignant Phenotype cell transformation is the direct result altered by protein
products expression generated by point mutations in codons 12, 13, and 61 of KRAS
(Vogelstein et al., 2013).
Blackford et al. (2009) demonstrated the best use of methodology and statistical
approach that helped explore the number of mutations in PC in association with cigarette
smoking. Given that smokers may develop the disease more frequently at a younger age,
the researchers found no difference between the mutation of driver genes among smokers
and non-smokers. The types and patterns of mutations found in PC, provided insight into
the mechanisms by which cigarette smoking causes the disease (Blackford et al., 2009).
While the mutations found on PC, have a strong association with cigarette smoking, the
findings in this study did not produce a characteristic profile. Like Crous-Bou et al.
(2007), Blackford et al. (2009) noted that previous researchers overlooked the distinction
between the passenger and driver mutations that explains the often unconvincing
associations between smoking and driver mutations. Recognizing this gap, and while
there are continued studies on different aspects of the PC genomic landscape, the intent
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of this dissertation is to provide a descriptive analysis of the prevalence pattern of PC and
CTSG-A known to have increased risk of extrapancreatic malignancies versus nonsmokers.
Connecting the Dots: Smoking and Genetic Aspects of Pancreatic Cancer
The lack of effective screening tests makes the detection and treatment of PC an
Augean task, albeit the substantial gains in the last 40 years on the knowledge of its
epidemiology. The past efforts into understanding the pathosis and epidemiology of PC
established the basis for scholarly introspection on many current inquiries focused on the
association of modifiable risk factors and inherited mutations. The goal of the past and
present studies falls largely within the confines of understanding the insights of genetic
alterations and specific modifiable risk factors. Much of the recent research concentrates
in this line of inquiry; therefore, recognizing the modifying effect of smoking to
individuals with family aggregation justifies the merit of this dissertation and future
endeavors.
Parallel to the study of Klein et al. (2004), Wolfgang et al. (2013) found the
significant role of tobacco use in the etiopathogenesis of PC to higher smoking rate
among first-degree family relatives (FDRs) of individuals diagnosed with the disease.
The findings in these studies suggest that smoking cessation may be particularly useful in
the familial PC kindreds. Kumar et al. (2014) also examined the pathopoiesis mechanism
of tobacco use in early stage PC using genetically engineered mouse model (LSL-KrasG12D). The study found accelerated formation of pancreatic intraepithelial neoplasia
(PanIN) lesions in response to smoking and the switching of markers from acinar to
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ductal type, suggestive to enhanced acinar-to-ductal metaplasia (ADM). In this study, the
experimental epidemiological data provided a novel mechanism of smoking that induced
ADM in the presence of constitutively active KRAS mutation. The findings of Kumar et
al. (2014) enhanced the existing body of knowledge on the role of smoking in the
etiopathogenesis of PC and opened the gap on the need to explore its modification effect
among individuals with CPG.
Hart, Kennedy, and Harvey (2008) asserted the need for further epidemiologic
work in clarifying the association of PC with many exposures using a precise
measurement of risk factors, and adjustment of potential confounders. Schenk et al.
(2001) conducted routine questioning of patients on the family history of PC, the age of
onset of the disease among relatives, and patient’s smoking status. The study assessed the
higher risk of PC in FDRs, and the effect of smoking on disease onset among younger
individuals. Schenk et al. (2001) found that while family history of PC, the age of onset
of the disease among relatives and patient’s smoking status may identify individuals at
high risk, it is vital to explore the genetic and environmental interactions (GEIs)
associated with the disease in future research. The only way to move forward in any
research endeavor is to revisit the outcomes of past and ongoing studies. From this
overview, it is clear that numerous research on the role of smoking and CPG in the
etiopathogenesis of PC has contributed to the understanding of the epidemiology of the
disease. The findings of these studies support the unique probable contribution of this
dissertation to the existing body of knowledge, generating a snapshot of a possible
correlation of smoking, gender, and age to the development of PC and CTSG-A,
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enhancing the knowledge on the pathopoiesis mechanism of these predictors in disease
induction and promotion. The plethora of findings of the past and present studies
highlighted the causal significance of modifiable risk factors and genetics in the pathosis
of PC. It would be worthy to discuss further in this chapter its epidemiology, and the
genetic basis of its development and progression.
Bridging Cancer Epidemiology and Social Evolution
Modern epidemiology is a direct result of the paradigm shift from a populationbased (upstream) to a downstream (individual) approach. The impact of modern
epidemiology such as ‘molecular’ and ‘genetic’ epidemiology (Loomis & Wing, 1990;
Diez-Roux, 1998) requires an explanatory power that largely dependent upon the
advances in technology and information systems. The development of the new
epidemiologic shift recognizes not only the significance of sophisticated technologies that
go beyond the established genome, proteome, and gene expression platforms, but also
new techniques of study design and data analysis (Pearce, 1996; Verma, Khoury &
Ioannidis, 2013). Given the remarkable progress in the last decade in advanced
technology and new methods for biologic measurements, the reductionist approach of
modern epidemiology often ignored the major causes of disease. Pearce (1996) argue that
epidemiology must reintegrate itself into public health and must rediscover the
population perspective. However, while the new paradigm could produce a lifestyle
approach to social policy, the cumulative outcome of research in cancer epidemiology
could equate positive implications to population health.
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The key figures in the new epidemiologic model not only acknowledges the
development of new techniques of study design and data analysis but also recognize the
need for a multidisciplinary approach (social, biologic, statistical), and specifying the
population group as the unit of study (Susser, 1985). While occupational carcinogens can
be controlled with some difficulty through regulatory measures (Pearce, 1996), it is
important to acknowledge the fundamental problem of tobacco use is not by its
consumption but lies in its production. Pearch (1996) focused on some of these
fundamental changes in epidemiology over the past few decades and considered the
concepts of causality involved, as well as their ideological and practical consequences.
While smoking cessation is the probable social implication of this dissertation, it is
important to stress the epidemiologic value of a study on the apparent correlation
between gender and age, modification effect of tobacco use among individuals with PC
and CTSG-A. The outcome of a risk factor epidemiologic study in individual terms could
uplift precision medicine to meet the challenges in tailoring medical interventions based
on patient’s biological profile, genetic and epigenetic traits, giving a better understanding
of EGBIs.
Embraced by both biomedical and social determinist frameworks, the interlinking
of the traditional epidemiologic level of intervention (upstream or distal) and the modern
epidemiologic level of intervention (downstream or proximal) put public health in the
conundrum of the proximal-distal divide. Signal the importance of the argument of the
2008 study of Krieger in replacing the terms proximal and distal from the public health
lexicon, supports the recommendation of Wemrell et al. (2016) on the critical need for
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open interdisciplinary debates on the contribution of social theory to the epidemiological
inquiry. While coping with the demand of the 21st-century, global health could still be
viewed and approached within the mindset of traditional epidemiology, and the purview
of molecular and cancer epidemiology.
The discovery of tobacco smoking as a cause of lung cancer in the early 1950s
gave the field of epidemiology its recognition (Pearce, 1996), shifting the epidemiologic
paradigm in the object of study in the mid-20th century on the role of multiple causes.
Establishing the correlation of age, gender a modifiable risk factor (smoking) with PC
and CTSG-A requires the use of early and current epidemiologic theories, and
contemporary mainstream epidemiologic concept coalescing to a UPCC. The complex,
integrative approach of UPCC supports the views of Loomis, and Wing (1990), Pearce
(1996), and McEwen and Getz (2013) in embracing the new epidemiologic paradigm
congruent to the advances in cancer genome sequencing. Theorizing the pathopoiesis
mechanism of smoking, inherited genes, and association of gender and age in the
etiopathogenesis of PC/CTSG-A warrants exploration of its causal footprints, conjoining
both biomedical and lifestyle (Krieger, 2011).
In this dissertation, follow-up and future research are highlighted on the role of
molecular epidemiology in emphasizing individual susceptibility to PC will assess the
relative contribution of modifiable risk factors to non-modifiable genetic factors. In this
premise, the etiopathogenesis of the disease could be explored from the bottom up.
Bridging cancer epidemiology and social evolution will be dependent upon the
incorporation of the strength of the social network and social contagion theory. The
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testable assumption of the social network theory as its strength states that the social
structure of the network itself be primarily responsible for determining individual
behavior and attitudes by shaping the flow of resources which determines access to
opportunities and constraints on behavior (Berkman et al., 2000). Why choose if a single
theory cannot make a change? Incorporating these ideas in addition to the composite and
underpinnings of UPCC could springboard a priori argument on the role of social
networks in the spread of an intervention such as smoking cessation, or amplifying the
promotion of the significance of early screening to improve mortality and morbidity.
While the causal nature of peer effects could be associated with tobacco use; the
social contagion theory of Christakis and Fowler (2013) set an argument on human social
networks exhibiting a “three degrees of separation.” Such association could support the
assumption of spreading the interpersonal influence the acknowledgment of the
significance of early screening, and the promise of a novel therapeutic approach. Like the
widely discussed classic paper of Travers and Milgram (1969) on ‘six degrees of
separation,’ the three degrees of separation or the three degrees of separation rule
(Christakis & Fowler, 2009) agreed on the premise that telegraph phrases are meant to be
evocative, and not definitive. For example, the role of interpersonal influence in
spreading novel ideas such as advances in early screening to achieve a greater therapeutic
outcome. The preponderance of the evidence that points to the added significance of a
passive-broadcast viral messaging to create social contagion warrants the recognition of
the approach. Taking into account factors such as the promise of the outcome of a
research study in the quality of life, social and economic incentives could expand the
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social network and amplify social support needed by individuals with PC or any deadly
diseases. According to Kroenke et al. (2013), effective social support interventions need
to evolve beyond social-emotional interventions and need to account for disease severity
and treatment status.
Personal Genomics, Screening, Surveillance, and Management
Reducing the cancer-specific mortality of PC lies in early diagnosis and treatment
(Lennon et al., 2014). Ideally, early detection of the disease should be at precancerous
stage, and according to Lennon et al., (2014) there are six issues needed to be addressed.
First is the characterization of the curable lesions, distinguishing the advanced from noncurable. Second, identify the reasonable window of opportunity to detect localized
treatable lesions. Third, development of a test or screening tools that could determine the
compendium of curable localized lesions. Fourth, a method to assess and distinguish
localized lesions that are treatable from localized lesions that have a reasonable chance of
progression. Fifth, development of novel screening tests or biomarkers with high positive
predictive value. Lastly, the continued evidence-based research on the significance of
early screening as well as research on the understanding of PC’s biological processes that
have potential implications for the understanding of its etiology, prevention, and therapy.
Driven by the accumulation of somatic mutations, PC epigenetic modifications, and
changes in the microenvironment warrant new strategy to investigate disruptions of gene
expression networks that could uncover key regulators and pathways in carcinogenesis
(Hoskins et al., 2014).
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The utilization of population-level screening tests utilizing registered tomography
(CT) despite neither indisputable confirmation nor proficient assertions about the
adequacy and cost-viability has been promoted to patients through dissemination into
practice on amid the previous decade (Burger and Kass, 2009). Inquiries regarding
doctors’ proficient roles and responsibilities within the setting of medical advancement
shroud this phenomenon, including the appropriate scope of patient autonomy and access
to unproven screening technology. Burger and Kass (2009) recognize the medical and
ethical contrasts between screening recommendation for an individual patient and a
population health premise. Particular cases were examined to investigate how risk
factors, evidence, and inclinations impact singular patient screening choices. Direction on
how screening ought to be done is obscured by specialists’ attention on ethics,
communication, and governmental issues. The proposal of Rychetnik et al. (2013) on
expanded evidence-based cancer screening policy and practice could yield significant
implications on cancer screening research. Stadler et al. (2012) analysis of the literature
found the association of both BReast CAncer gene one (BRCA1) and BRCA2 mutations
with the incidence of pancreatic cancer and BRCA2 mutation in the increased risk of
developing PC. Lucas et al. (2014) proposed environmental and genetic factors as causes
of PC with BRCA2 gene as the genetic factor of particular importance. The risk of
pancreatic cancer increases in the individual who has a close relative with the disease,
with approximately 5-10 % believed to show familial clustering (Lynch et al., 2004;
Cavanagh & Rogers, 2015). According to Naderi and Couch (2002), PC and germline
BRCA2 mutations have a younger than average age of onset and tend to be of Ashkenazi
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Jewish descent. Cavanagh and Rogers (2015) stated that cancer cases among individuals
with CPG might be due in part to environmental factors or other genetic factors rather
than possessing a BRCA1/2 gene mutation. Parallel to this argument, this dissertation
hopes to inquire about the presumable alteration impact of smoking as a biological and
modifiable hazard in the PC/CTSG-A induction and promotion.
Epidemiological theory as argued by Krieger (2011) is the practical necessity of
thinking about and explaining disease distribution. The combined views of Fernandez, La
Vecchia and Decarli (1996), Lynch et al. (2009), and Maisonneuve and Lowenfels (2010)
postulates that the key measures to reduce PC are primary prevention in the form of
tobacco smoking control or smoking cessation. In this context, given the cornucopia of
knowledge proliferation from germ theory at its inception to the emerging scientific
theories on cancer dynamics initiated by the classical evolutionary principles of the
Darwinian theory (Barbara et al., 2014) forms an integrative web of theoretical causations
that supports the proposed metatheory in this dissertation referred to as UPCC.
Evolutionary models and theories vary substantially between gene and culture (Claidière
& André, 2012). Richerson and Boyd (2000) added to this debate the methodological
approach of the Darwinian theory. Darwinism is a collection of concepts, empirical
methods and mathematical tools designed to understand the dynamics of genetics and
cultural evolution (Richerson & Boyd, 2000). Therefore, this dissertation supports the
rationale of cultural value transmission of smoking cessation that could lower the risk to
individuals with CPG. Smoking cessation as a cultural item is a clear implication for
positive social change.
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The dynamic interplay of gene-culture transmission recognized in UPCC could
initiate the evolution of culture that embraces the value of evidence-based screening,
surveillance, management, and personal genomics. Central to human adaptations is the
use of socially learned information (Richerson, Boyd & Henrich, 2010), from literacy
program of a health system, emphasizing the significance of 21st-century approach. The
combined causal association of a variety of levels as recognized by Lynch and Rebbeck
(2013) that are linked to cancer incidence and mortality justify the supposition of UPCC.
It is critical to underscore the magnitude of intercalating the mandatory early screening,
and management of the health system. Moreover, it is also vital to showcase the weight
of the cumulative evolution of complex adaptations on the invaluableness of genomics to
gene-culture coevolution. Acknowledging the health system as a macroenvironment
factor, in addition to social determinants and environmental exposures such as smoking
will improve intervention, translation, and implementation.
While the 2013 study of Lynch and Rebbeck presented the MBASIC to integrate
macroenvironment and individual factors with biology; UPCC as an integrated
framework acknowledge the significance of embracing personal genomics, evidencebased surveillance, screening, and management rooted in a culturally transmitted
macroenvironment. Should we be tampering with the human genome? The ethical, social,
and clinical implications of personal genomics continue to trigger debate among research
communities. Such discussions are a much-needed equipoise to the value of personal
genomics for understanding disease pathogenesis, vital to improving the prognosis of a
deadly disease like PC (McGuire et al., 2007; Zakharova et al., 2012; Nagpal et al.,
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2014). Parallel to this view, Canto et al. (2013) purport the merit of surveillance,
screening, and management of high-risk individuals (HRI) with an inherited
predisposition to PC, establishing a consensus that high-risk individuals warrant
pancreatic screening. An earlier study of Canto et al. (2012) asserted the need for
continued research for optimal method of screening people with an inherited increased
risk for PC. In this study, the researchers conveyed that rather than focusing screening
efforts to detect invasive cancers, PC screening, and surveillance program should be in
identifying and selectively treating asymptomatic high-grade precursor neoplasms.
Debates over these issues, Zakharova et al. (2012) further argue the need for evidencebased consensus on the optimal preoperative imaging assessment of patients with
suspected PC and a unified definition of borderline resectable tumors. Given that multidetector computed tomography has been widely accepted, it is necessary to embrace a
realistic approach concerning the patient’s age, health status, quality of life and recovery
after surgery. The practical approach discussed in this study on screening, surveillance,
and management, as well as the improvement in the early detection and prevention, is
dependent upon the progress in the understanding of the genetic alterations in PC and
associated precursors and development of biomarkers.
New Public Health Meets a New Initiative on Precision Medicine
There has been a rapid expansion of knowledge about human DNA structural and
sequence variation, since the completion of the Human Genome Project (HGP) in 2001
(Hood & Rowen, 2013). The growth of publicly available data sets and literature mining
databases inspired by the HGP’s open approach to data sharing gave way to the
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identification of commonly dysregulated gene expression networks in pancreatic ductal
adenocarcinoma (PDAC) that could provide insight into the mechanisms of tumor
progression (Califano et al., 2012). PDAC is the most common sporadic pancreatic
cancer, driven by the accumulation of epigenetic modifications, somatic mutations and
changes in the micro-environment (Hoskins et al., 2014). A genome-wide approach was
used by Hoskins et al. (2014) to profile gene expression changes between normal derived
pancreatic samples and tumor. The data examined in this study in the context of
expression gene sub-networks, implicated a novel, central role for hepatocyte nuclear
factor 1 alpha (HNF1A) and corroborated the benefits of HNF1A down-regulation in the
proliferation and survival of pancreatic tumor cells. HNF1A is a transcription factor that
is known to maintain homeostasis of the endocrine pancreas that regulates pancreatic
differentiation (Luo et al., 2015). Evident in murine Sleeping Beauty transposonmediated somatic mutagenesis models of pancreatic cancer, Biankin et al. (2012)
identified various and diverse somatic aberrations in genes described traditionally as
embryonic regulators of axon guidance, particularly slit glycoprotein (Slit) and
Roundabout receptor (Robo) signaling. The study provided further supportive evidence
for the potential involvement of axon guidance genes in pancreatic carcinogenesis (p. 3).
The burden of chronic diseases such as PC is often neglected on the public
agendas. The increasing annual economic burden of PC is beyond genetics and social
inequalities, making it necessary to embrace the shift in the level of analysis from
traditional to modern epidemiologic and New Public Health approach. The significance
of the successful delivery of the New Public Health both at the level of society and
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individual behavior (Halpin et al., 2010) justifies the intent of this dissertation on the
need for further exploration of the pathopoiesis mechanism of tobacco use and FCH, the
etiopathogenic role of gender and age. The unveiling of the “Precision Medicine
Initiative” during the State of the Union Address of President Barack Obama on January
20, 2015, springboard the new effort of revolutionizing a new model of patient-powered
research that could accelerate biomedical discoveries and provide clinicians with new
tools, knowledge, and therapies. A near-term focus on cancers with a longer term aim to
generate knowledge applicable to the whole range of health and disease are the two main
components of this initiative (Collins & Varmus, 2015). In response to this initiative,
Francis Collins, director of the National Institutes of Health and Harold Varmus, director
of the National Cancer Institute acknowledge the near-term promise and the long-term
benefits of precision medicine that not only requires global collaborations with related
projects, but also motivating and attracting visionary scientists from many disciplines.
The avidity of renewed debate on enhancing population health and well-being of the
least-advantaged people will be dependent upon the success of this initiative with the
assumption that precision medicine will contribute to the advancement of the health of
the public and clinical practice. While Bayer and Galea (2015) question the full potential
of precision medicine, Collins and Varmus (2015) highlighted what it could offer to the
continued advancement of genomics and the new era of evidence-based disease-specific
medical care without compromising patient privacy.
The downstream level of intervention of modern epidemiology through the
provision of clinical preventive services such as screening and surveillance in concert
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with public health programs could help explain the complex pattern of pancreatic cancer
death (McLean, Williams & Lamont, 2013). The complementary role of outcomes
research and epidemiology (Roger, 2011) can give way to improve the quality of care, as
well as provide powerful and unique insights on efficient therapeutic approach. The
practice of developing targeted interventions or medical treatments based on a person’s
environment, genetics and lifestyle are under the national microscope following the
Precision Medicine Initiative (McGill, 2015). Precision medicine could readily reduce the
incidence of PC by directing the focus on predictive testing on high-risk individuals
before the likely onset of the disease. In the public health sphere, the advances in the
genomic technology could identify those who unknowingly harbor a mutation in their
genome, allowing for actionable interventions and a greater focus on disease prevention.
Summary
Strategies designed to improve the quality of life and survival rate of patients
diagnosed with PC needs the continued progress in the identification of novel therapies
(Hidalgo et. al, 2015). The genetic complexity of this lethal disease warrants the
understanding of the Whole-exome and Whole-genome sequencing that will further
advance the understanding of the etiopathogenic role of gender and age, in addition to
pathopoiesis mechanism of smoking to PC/CTS-GA. Moreover, the dynamics of clonal
diversification and selection are critical to understanding neoplastic progression and
response to therapy (Greaves & Maley, 2012). Understanding and preventing therapeutic
resistance lies in the continued research addressing the many fundamental questions in
pancreatic cancer biology from the order of progression and mutation processes. The low
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survival rates associated with this disease makes it critical to focus on improved
outcomes and development of screening modalities to identify PC while the tumor is
localized and amenable to surgical resection (Poruk et al., 2013). While Poruk et al.
(2013) found that the incidence and population death rate from PC is high enough to
consider population-level screening, the possible barrier to initiating screening strategy is
the affordability and availability of a screening test with sensitivity and specificity of
90% that could identify PC patients at a resectable stage.
Recognized by the “Precision Medicine Initiative,” personalizing treatment
according to the presence of molecular targets could improve outcomes for patients with
diseases with poor prognosis such as PC because of its genetic landscape (Chantrill et al.,
2105). The different theories discussed in this chapter that embody the UPCC help
explain GEIs justifying the gap being explored in this dissertation. Smoking cessation
and acknowledgment of the value of personalized screening are cultural items that could
induce positive socio-cultural transformation. Both in the context of traditional and
modern epidemiology, equitable distribution of health-enhancing technologies,
information, and treatments will help facilitate more rapid uptake and use of new health
information among groups with lower SES, eventually reducing cancer mortality and
achieving health equity (Rubin et al., 2014). Further research on the association of
genetics and environmental interactions are critically important (Schenk et al., 2001).
Likewise, Greaves and Maley (2012) asserted the promise of exciting clinical
opportunities by focusing directly on the evolutionary adaptability of neoplasms and
designing interventions to slow and direct, or control PC progression. The delivery of the
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New Public Health both at the level of society and individual behavior (Halpin et al.,
2010) justifies the importance of lifestyle change to reduce cancer risk, as well as its
significance in prevention, and control of PC progression. Under the lens of Public
Health and modern epidemiology—the study design, sampling, and statistical approach
will be discussed in the following chapter.
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Chapter 3: Research Method
In the previous chapter, current theory-driven literature was reviewed addressing
the specific components of pancreatic cancer epidemiology. In the review of the
literature, I also examined the different risk factors, the significance of screening and
surveillance, and the importance of genetic sequencing in defining the genetic blueprint
of pancreatic cancer. Given the new opportunities created by recent genetic discoveries to
improve the understanding of the molecular summation of pancreatic neoplasms, the
outcome of this study could provide a meaningful addition to the existing body of
knowledge on early detection and personalized treatment. To the best of my knowledge,
the etiologic risk factors within hierarchical levels, bridging the gap between individual,
macroenvironmental, and biologic levels, have not been examined under the lens of
modern epidemiology and public health. The gap on the modification effect of smoking,
age, and gender of individuals with CPG justified the intent of this study. A theory-driven
approach, as argued by Chen and Rossi (1983), will compensate for shortcomings of
research designs that do not meet the high standards of a randomized controlled
experimental model.
According to Lynch and Rebbeck (2013), most multilevel studies lack a focus on
the relationship between macroenvironment and individual-level factors, and the
traditional research on macroenvironment or individual-level factors remains broadly
defined without accounting for the PC genomic landscape. Lynch and Rebbeck
highlighted the need for full integration of biologic level elements with
macroenvironment and individual-level factors. Although smoking is strongly associated
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with PC, most smokers will not be diagnosed with the disease. On the other hand,
inherited mutations have a lower to high lifetime risk; some carriers may never be
diagnosed, even at an advanced age. Considering that risk factors assessed in isolation
and identified by a standard approach may not produce an in-depth evaluation of the
complex multifactorial causes of PC, I focused on exploring the etiopathogenesis of the
disease based on EGBIs at an individual level (smoking) and biologic level (inherited
susceptibility variants). This approach supported the cumulative effects innards and
across levels, or within at least two ways (see Table 3). The study design, sample, and
analytic approach are addressed in this chapter.
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Table 3
Hierarchical Level Definitions
Level

Sublevel

Factors at this level can serve as:

Macroenvironment

•

Health policy
(national, state, local
Community,
neighborhood
Social and built
environment
Practice setting and
care providers
Family and social
support

•

Behaviors
Exposures
Psychologic
determinants
Socioeconomic
factors

•
•

Exposures leading to disease
Intermediate between the
macroenvironment and disease

Tissue
Cell
Somatic genome
Inherited genome

•
•

Processes leading to disease
Intermediates and biomarkers
reflecting the relationship between
macroenvironmental and individual
factors

•
•
•
•

Individual

•
•
•
•

Biologic

•
•
•
•

•
•

Exposures that affect individual risk
factors
Exposures that affect biologic
processes
Contextual variables (Rebbeck et al.,
2010)

Note. From “Context-dependent effects of genome-wide association study genotypes and
macroenvironment on time to biochemical (prostate-specific antigen) failure after
prostatectomy” by Rebbeck et al., 2010, Cancer Epidemiology Biomarkers & Prevention,
19(9), 2115-2123.

61
Study Design and Approach
The causality of tobacco-related mutagenic risk factors and the correlation
between gender and age and CPG will not only raise awareness of the significance of
cancer risk screening and counseling but will also increase the understanding of
environmental, genetic, and biodemographic interaction (EGBI) contributing to the
development and progression of PC. The results of this study may be used to promote
lifestyle change in reducing cancer risk. Improving the perceived corollary of individuals
with inherited genes and quality of life during the expression or final stage of the disease
is dependent on the favorable adjustment of behavioral risk factors. The intent of this
study was to explore the association between smoking, gender, and age in individuals
with CPG. I used a cross-sectional design to determine the prevalence of pancreatic
cancer and CTSG-A among smokers to answering the research questions:
RQ1: Is cigarette smoking associated with the etiopathogenesis of pancreatic
cancer and cancer types with shared gene association (CTSG-A)?
H01: Smoking level has no correlation with prevalence of PC and CTSG-A.
H1: Smoking can increase the risk of PC and CTSG-A.
RQ2: Is there a relationship between the combined role of age and gender in the
etiopathogenesis of PC and CTSG-A?
H02: Age and gender have no correlation with prevalence of PC and CTSG-A.
H2: Age and gender are correlated with the prevalence of PC and CTSG-A.
The overall risk of nonsmokers remains elevated in former smokers for up to 10
years or more, although smoking cessation lowers this risk of PC by up to 50% (Iodice et
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al., 2008; Macleod & Chowdhury, 2006). The potential association of smoking, gender,
and age as predictors of the outcome variable (PC/CTSG-A) were explored using a crosssectional design. The sample size was determined using G*Power (Version 3.1.9.2).
Given that estimating joint and marginal probabilities was not possible, investigating
independence of D (PC) and E (Exposure: Smokers in association with PC/CTSG-A)
nonsmokers with PC and CTSG-A was still possible. Secondary data were recoded and
randomized using IBM Statistical Package for the Social Sciences (SPSS, Version 23, 64bit edition). Although logistic regression makes no assumptions about the distributions of
the predictor variables (smoking, gender, age), ordinal modeling was the fundamental
property of the design of this study to test whether smoking level and age are effect
modifiers to inherited genes or combined causative predictors in the induction and
promotion of PC and CTSG-A. Regression procedures were used to examine the role of
smoking in driving the initiation and progression of the disease in individuals with CPG
(see Schaal, Padmanabhan & Chellappan, 2015). The odds of correlation or its combined
interaction were examined using ordinal regression analysis.
According to Knol and VanderWeele (2012), the gap on presenting the analysis of
effect modification and interaction showed that only 11% of cohort studies and casecontrol studies presented individual effects of both exposures and the joint effect of both
exposure; therefore, it was necessary to assess overall interaction measures. The intent of
this dissertation was to explore whether smoking (Q) contributed to the increased risk
among individuals with FCH or CPG (E) on PC (D), where Q, D, and E were
categorical/ordinal. Given the importance of presenting sufficient information and
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drawing a statistically significant conclusion, I adopted the recommendations of Knol and
VanderWeele and included OR and RR. Given that quantitative interaction is sometimes
referred to as synergism or antagonism, interaction or its combined association was
explored, which may be of public health interest considering that the effect of CPG as the
primary exposure (see Figure 3) may vary across the subgroup (smokers, gender, age)
and could give light to the significance of surveillance and early screening and the
importance of behavioral change.
The dependent variable under Level 1 or Category 1 in this dissertation comprised
cancer types with P16(CDKN2A) and PRSS1 mutations. Known as cyclin-dependent
kinase inhibitor 2A (CDKN2A gene), p16 gene mutations occur in PC with 10-20%
approximate risk and 20-34 times greater than that reported in any other tumor type (see
Tables 1 and 2). Numerous additional studies have indicated a high frequency of p16
deletion in melanoma, esophageal, lung, pancreas, mesothelioma, bladder, head, and
neck, breast, acute lymphocytic leukemia, brain, osteosarcoma, ovarian, and renal cell
lines (Rocco & Sidransky, 2001). The mutations in the serine protease 1 gene or PRSS1
(Yi et al., 2016) were found to be a major factor of PC according to Zeng et al. (2011),
with 50% approximate risk and 25%-40% risk by age 70 according to Lowenfels et al.
(1997). The cancer types that were included as part of this category were pancreatic,
melanoma, esophageal, leukemia, lung, bladder, renal, brain, osteosarcoma (bone), and
cancer of the head and neck.
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Figure 3. Q = Smoking, X = Genetic syndrome and associated gene(s), CPG (E), PC (D).
Level two or category two includes cancer types with BRCA1, STK11, and LKB1
mutations. While p16 is related to breast cancer, BRCA1 is two times to have a relative
risk of PC, with higher risk by age 70. The human LKB gene (official HUGO symbol,
STK11) encodes a serine/threonine protein kinase that is defective in patients with PeutzJeghers syndrome (PJS). Mutations occur particularly in lung and colorectal cancer
(Launonen, 2005). The cancer types that are considered to be part of this category are
breast, ovarian, and prostate cancer.
Level three or category three are composed of cancer types with bMLH1, and
bMSH2 mutations. While the risk by age 70 is <5%, hereditary cancer syndromes that
infer high cancer risks, require intensive cancer surveillance (Pearlman et al., 2017). It
was suggested by Pearlman et al. that given the high frequency and broad spectrum of
mutations, genetic counseling and testing are highly recommended. The cancer types in
this category are endometrial, colorectal, and stomach cancer.
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Setting and Sample
The secondary data in this study was from the 2014 Behavioral Risk Factor
Surveillance System (BRFSS). Following the standards suggested for secondary analysis,
descriptive and ordinal logistic regression will be performed (see Figure 4).

Figure 4. Epidemiologic data processing tree. (Based on the 2014 BRFSS and
hypothetical conceptual cohort).

Description of the Study Population
The population for the study was defined as participants of the 2014 BRFSS
survey. Subject selection criteria were set narrowly, by selecting specifically those who
smoke and do not smoke with PC/CTSG-A (survivorship module), versus non-smokers
with PC/CTSG-A. Subjects with PC/CTS-GA are those identified with inherited
susceptibility variants (Table 1, Table 2). Association between smoking, age, gender, PC,
and PC/CTSG-A are explored using hypothetical conceptual cohort. A hypothetical
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conceptual cohort is defined as participants from the 2014 BRFSS survey who qualified
as high-risk based on the level of smoking.
Sampling: Power Analysis
In this dissertation, like any cancer research or any other studies, the calculation
of the sample size is critical, as well as the equal chance of every individual surveyed in
the 2014 BRFSS in a target population to be included in the sample. It is important to
remember that while random sampling is the gold standard of a sampling strategy,
random sampling does not describe the sample or its size as much as it describes how the
sample is chosen (Kadam & Bhalerao, 2010). Integral in generating ethically and
scientifically sound results is to calculate the optimum number of required sample. Given
the calculation of adequate sample size is pivotal, it is essential to remember that both the
practicality of testing methodology and the statistical significance of the sample size are
similarly critical. According to Kadam & Bhalerao (2010), the sample size for any study
is dependent upon the power of the study, expected sample size, an acceptable level of
significance, standard deviation and underlying event rate in the population. The “level of
significance” in this dissertation is a significant p-value of <0.05. A power analysis
(computed a priori: required sample size – given α, power, and effect size) was
performed to estimate the effect size using G*Power (Version 3.1.9.2). While in large
studies, the power is occasionally set at 90% to reduce the 10% possibility of a “false
negative” result, I will accept a power of 80% with a total sample size of 116 (see Figure
5). However, the sample size of 116 after power analysis (PA) failed the ordinal logistic
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regression assumptions; therefore, the remaining sample after data cleaning was utilized
in this dissertation.

Figure 5. Power analysis.

Instrumentation and Materials
Conceding the fact that the sample and source of the secondary data already
discussed and defined in this chapter, I would direct the focus to the instrumentation and
materials required to conduct this dissertation. A description of the processes, dataset,
and data collection tools is discussed.
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Eligibility Criteria, Data Set, and Data Collection Tools
Subjects were selected at random and re-coded after I received IRB approval
(approval number 12-19-16-0390363). Variables in the data sets are identified under the
core section (tobacco, gender, age), “cancer survivorship” module of 2014 BRFSS
survey. Relevant data was kept using data storage device (USB flash drive), a backup
copy was uploaded to Microsoft OneDrive (Version 8.17.7).
Assessment of the Reliability and Validity of the Data
The key assumptions of this dissertation are strengthened by the reputation of the
Behavioral Risk Factor Surveillance System (BRFSS) as the nation’s premier system of
collecting data on health-related behaviors, preventive services use and chronic health
conditions. While the causes of most PC remain unclear with a 5-10% run in families, the
reliability and validity of BRFSS data will help justify the significance of expanded
BRFSS, highlighting the need for adding cancer specific modules. Such modules could
help connect the association of modifiable risk factors and shared genes in the initiation
of cancer development.
Data Collection and Analysis
Data sets of 2014 BRFSS survey was obtained using a data storage device (USB
flash drive), and a backup copy was uploaded online using Microsoft OneDrive (Version
8.17.7). Extracted data will be exported, and re-coded using IBM Statistical Package for
the Social Sciences (SPSS, Version 23, 64-bit edition). Biologically plausible
relationships between smoking, gender, and age in the initiation and progression of PC is
quantified using regression methods. While it is relatively easy to consider an additional
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in regression models, only variables that are clinically meaningful were included in this
study. Regression methods were used to assess and adjust for confounding, and determine
whether there is effect modification, as well as simultaneously evaluate the relationships
of risk factors (smoking, age, gender). Given that this study involves PC/CTSG-A, and
more than one independent variables, ordinal logistic regression analysis was performed
to assess confounding and effect modification. The impact of multiple risk factors
(smoking, gender, age) is examined as opposed to focusing on a single risk factor. Two
separate logistic regression analyses (see Table 18A-C) was conducted to assess
differences in induction and promotion of pancreatic cancer/CTSG-A by gender and three
age groups (<51, 52-69, 70>). According to Langkamp, Lehman, and Lemeshow (2010),
the technique of dropping cases with missing data should be discouraged; but in this
study, the sample size was big enough to drop missing attributes, and stratified sampling
will optimize generalizability.
Summary
The population for this study was defined as participants of the 2014 BRFSS
survey. The study is a cross-sectional model to examine the association of smoking, age,
and gender or its combined causality to individuals with PC/ CTSG-A. Secondary data
was re-coded and randomized through stratification, and regression modeling was
performed using IBM Statistical Package for the Social Sciences (SPSS, Version 23, 64bit edition). Countering the threats to external and internal validity was guided by the
consideration of the importance of generalizability of the research data, passing the
assumptions of the statistical analysis used, and stratification to deal with possible
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confounders. The result of this examination will not only bring to light the
noteworthiness of cancer risk screening and counseling but additionally will expand the
understanding of the evolution of PC/ CTSG-A. The expected promise of this study will
give light to the importance of lifestyle change to reduce cancer risk, promote prevention,
and control of PC progression. To the best of my knowledge, exploring the etiologic risk
factors within hierarchical levels, bridging the gap between individual,
macroenvironmental and biologic level has not been examined under the lens of modern
epidemiology and public health. The findings of the study could support the importance
of behavioral risk factor and their roles in reducing the prevalence of PC and CTSG-A,
enhancing the late-stage quality of life.
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Chapter 4: Results
The purpose of the study was to explore the association between smoking as a
shared environmental factor in individuals diagnosed with pancreatic cancer (PC) and
CTSG-A and risk of extrapancreatic malignancies. A cross-sectional design was used to
assess the burden of the disease and the need for public health intervention, planning, and
allocation of health resources. Although this study did not include a molecular
epidemiological analysis or provide information about the cause and effect of smoking
level and PC and CTSG-A (see Table 4B.2, Figure 7), the outcome could highlight the
significance of cancer-specific modules either as part of optional modules or expanded
BRFSS. The positive results of this study could establish a working hypothesis for a
longitudinal study addressing cause and effect, and could guide future improvements in
the cancer-specific BRFSS survey module or the development of a supernet
epidemiology surveillance system (SESS). SESS could spur an initiative to combine the
Surveillance, Epidemiology, and End Results Program (SEER), BRFSS, and other
monitoring networks in a single integrated system. Using a cross-sectional design could
determine the prevalence of PC/CTSG-A and other cancers influenced by a shared
environmental factor (smoking), essential to answering the research questions:
RQ1: Is cigarette smoking associated with the etiopathogenesis of pancreatic
cancer and cancer types with shared gene association (CTSG-A)?
H01: Smoking level has no correlation with prevalence of PC and CTSG-A.
H1: Smoking can increase the risk of PC and CTSG-A.
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RQ2: Is there a relationship between the combined role of age and gender in the
etiopathogenesis of PC and CTSG-A?
H02: Age and gender have no correlation with prevalence of PC and CTSG-A.
H2: Age and gender are correlated with the prevalence of PC and CTSG-A.
Although a cross-sectional cohort study is an underutilized design (Hudson, Pope,
& Glynn, 2005), it could be used to assess the association between exposures (smoking
history/level) and the development of PC and comorbid cancer types. Missing attributes
were dropped after data cleaning, and stratified randomization was performed to achieve
optimum representation of the survey population. Table 4A and Figure 6 shows the six
states (Alaska, Iowa, Mississippi, Missouri, Nebraska, and Wisconsin) that used the
“cancer survivorship” module of the 2014 Behavioral Risk Factor Surveillance System
(BRFSS) survey. Instead of the suggested sample size from power analysis noted in
Chapter 3, to achieve generalizable results I used the remaining sample size of Nebraska
BRFSS data sets based on the distinct CTSG-A as compared to Alaska, Iowa,
Mississippi, Missouri, and Wisconsin. To provide a good picture of probable associations
between the dependent (PC and cancer types with S-GA) and independent variables
(gender, sex, smoking history/level, age), I estimated the prevalence of the dependent
variable grouped according to CTSG-A at a single point in time (see Table 4C). I
conducted ordinal logistic regression after recoding cancer types by prevalence
proportion (PP) and evidence for shared association with PC.
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Table 4A
Cancer Survivorship BRFSS Module by State FIPS Code

Frequency
Valid

Percent

Valid Percent

Alaska FIPS-2

431

6.0

6.0

Iowa FIPS-19

1150

16.0

16.0

Mississippi FIPS-28

608

8.5

8.5

Missouri FIPS-29

1103

15.4

15.4

Nebraska FIPS-31

3003

41.9

41.9

Wisconsin FIPS-55

874

12.2

12.2

Total

7169

100.0

100.0

Figure 6. CA survivorship module participants based on state FIPS.
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Table 4B.1
Case Processing Summary After Data Cleaning
Cases

CA Type Accdg. to SG-A *

N

Percent

Total

Percent

N

Excluded

Percent

Included

N

1691

100.0%

0

0.0%

1691

100.0%

1691

100.0%

0

0.0%

1691

100.0%

1691

100.0%

0

0.0%

1691

100.0%

Respondents Gender
CA Type Accdg. to SG-A *
Four-Level Smoking Status
CA Type Accdg. to SG-A *
Three Age Group

Table 4B.2
Snapshot of CA Type According to SG-A*Independent Variables
Respondents Gender

N

% of Total Sum

% of Total N

Male

692

36.9%

40.9%

Female

999

63.1%

59.1%

Total

1691

100.0%

100.0%

Current-Smokes Everyday

124

7.0%

7.3%

Current-Smokes Some Days

36

2.0%

2.1%

Former Smoker

655

37.8%

38.7%

Never Smoked

876

53.1%

51.8%

Total

1691

100.0%

100.0%

<51

126

7.0%

7.5%

52-69

659

37.8%

39.0%

70>

906

55.2%

53.6%

Total

1691

100.0%

100.0%

Four-Level Smoking Status

Three Age Group
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Figure 7. CA type according to SG-A.
Prevalence Proportion
PC prevalence proportion (PP) and PP of other cancer types were grouped based
on shared association with PC/ CTSG-A (see Table 2) and computed to obtain the main
outcome measure.
Table 4C
Frequency Table of CA Type According to SG-A

Valid

Frequency

Percent

Valid Percent

P16(CDKN2A)/PRSS1

691

40.9

40.9

BRCA1/STK11/LKB1

769

45.5

45.5

bMLH1/bMSH2

231

13.7

13.7

Total

1691

100.0

100.0
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Number of cases in a defined population at one point in time
PP =
Number of persons in a defined population at the same point in time
PP = P16(CDKN2A)/PRSS1 ÷ 1691
= 691/1691
= 0.4086 x 100
= 40.9%
PP = BRCA1/STK11/LKB1 ÷ 1691
= 769/1691
= 0.4547 x 100
= 45.5%
PP = bMLH1/bMSH2 ÷ 1691
= 231/1691
= 0.1366 x 100
= 13.7%
Analysis
Defining the gene and environmental factors that lead to the induction and
promotion of the disease is essential to intervention and management development.
Snapshot of the frequency of PC and cancer type with CTSG-A was generated in
correlation to exposure variables using descriptive statistics. Frequency pattern of
outcome variables allocated by recoded categorical numbers assessed in association with
a dichotomous, polytomous, and continuous predictors (gender, smoking status, age).
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The ordinal dependent variable (cancer type according to the shared gene
association), and independent variables that are continuous, dichotomous and polytomous
(age, gender, smoking status) in this study passed the first two ordinal logistic regression
assumptions of my study design. There are four assumptions needed to be considered:
1. One dependent variable, measured at the ordinal level.
2. One or more independent variables that are dichotomous, continuous,
categorical or ordinal.
3. There should be no multicollinearity.
4. The presence of proportional odds.
Before moving on to test the above assumptions, the PLUM ordinal regression
procedure was run for the reliability of overall goodness-of-fit measures. Ideally, there
should be no zero frequency to move on in interpreting and reporting the goodness-of-fit
measures, or have 80% or more expected cell frequencies. The dataset before power
analysis (PA) has 4 (5.8%) with zero frequencies, versus 69.4% with zero frequencies
after power analysis. Therefore, the remaining sample size after data cleaning and recoding (before PA) was used in this dissertation. Assumption “3” was confirmed by
running linear regression procedure. Based on the coefficient table, tolerance values are
greater than 0.1 (the lowest is .349) with all the variance inflation factors are much less
than 10, indicative of zero multicollinearity problems.
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Table 5
Multicollinearity Test: Coefficientsa
Collinearity Statistics
Model

Tolerance

1

VIF

Respondents Gender

.933

1.072

Three Age Group

.967

1.035

Current-Smokes Everyday

.349

2.866

Former Smoker

.361

2.768

Never Smoked

.589

1.697

a. Dependent Variable: CA Type Accdg. to SG-A

Given that the data set passed assumption “3,” separate binomial logistic
regression is performed, followed by PLUM, and GENLIN procedure. Assessed by a full
likelihood ratio test to compare the fit of the proportional odds model to a model with
varying location parameters, X2(5) = 6.497 with a p-value of .261. The test of parallel
lines is suggestive to passing the assumption of proportional odds (assumption 2), as
noted in the difference between the models, and the p-value greater than .05 (.261).
Table 6
Test of Parallel Linesa
Model

-2 Log Likelihood

Null Hypothesis

191.698

General

185.202

Chi-Square

6.497

df

Sig.

5

.261

The null hypothesis states that the location parameters (slope coefficients)
are the same across response categories.
a. Link function: Logit.

After running the PLUM-ordinal regression, there are 4 (5.8%) with zero
frequencies; therefore having 94.2% expected cell frequencies is indicative of the
reliability of overall goodness-of-fit measures. Both the Pearson and deviance goodness-
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of-fit test was a good fit to the observed data with p-values >.05. The final model
statistically significantly predicted the dependent variable over and above the interceptonly model, X2(5) = 99.090 with a p-value < .001.
Table 7
Goodness-of-Fit

Chi-Square

df

Sig.

Pearson

38.011

39

.515

Deviance

41.325

39

.369

Link function: Logit.

Table 8
Model Fitting Information

Model

-2 Log Likelihood

Intercept Only

290.788

Final

191.698

Chi-Square

99.090

df

Sig.

5

.000

Link function: Logit.

While the “Tests of Model Effect” shows that smoking status has no significant
effect on the prediction of developing PC and CTSG-A; gender is statistically significant
predictor with p = .000, Wald X2(1) = 75.507. This predictor has a statistically
significant effect on the prediction of PC/ CTSG-A induction and promotion.
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Table 9
Tests of Model Effects
Type III
Source

Wald Chi-Square

Gender
Smoking Status
Age

df

Sig.

75.507

1

.000

2.038

3

.564

17.538

1

.000

Dependent Variable: CA Type Accdg. to SG-A
Model: (Threshold), Gender, Smoking Status, Age

The odds of male respondents developing PC and CTSG-A versus the female
respondents is .418 (95% Cl, .344 to .509) with a statistically significant effect, X2 (1) =
75.507, p-value < .0005. An increase in age (expressed in years) was associated with an
increase in the odds of developing the disease, with an odds ratio of 1.374 (95% CI, 1.184
to 1.595), Wald χ2(1) = 17.538, p < .0005.
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Table 10

-.005 .1965

-.390 .380

.001

Exp(B)

Interval for

Confidence

Exp(B)

.677

1.463

1 .000 10.00 6.682

14.991

Sig.

Upper

[CAType_SG_A

Lower

Parameter
Threshold

Hypothesis Test

Wald ChiSquare
df

Upper

Lower

B

Std. Error

95% Wald
Confidence
Interval

95% Wald

GENLIN Procedure Parameter Estimates

1 .980

.995

=1.00]
[CAType_SG_A 2.303 .2061 1.899 2.70 124.874
=2.00]
Male

7
-.872 .1003

- -.675

8
75.507

1 .000

.418

.344

.509

.

1

.

.

1.068
Female

0a

.

.

.

.

.

Current-Smokes Everyday

-.190 .1867

-.556 .176

1.039

1 .308

.827

.573

1.192

Current-Smokes Some Days

-.326 .3305

-.974 .322

.973

1 .324

.722

.378

1.380

Former Smoker

-.073 .1028

-.275 .128

.507

1 .476

.929

.760

1.137

1

.

.

1 .000 1.374 1.184

1.595

Never Smoked
Age
(Scale)

0

a

.

.318 .0759
1

b

Dependent Variable: CA Type Accdg. to SG-A
Model: (Threshold), Gender, Smoking Status, Age
a. Set to zero because this parameter is redundant.
b. Fixed at the displayed value.

.

.

.

.169 .467

17.538

.

.
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Table 11
CA Type Accdg. to SG-A * Predicted Response Category Crosstabulation

Predicted Response Category

CA Type
P16(CDKN2 Count
Accdg. to SG- A)/PRSS1
% within CA
A
Type Accdg. to
SG-A

P16(CDKN2A/PRSS
1
379
54.8%

BRCA1/STK Count
11/LKB1
% within CA
Type Accdg. to
SG-A
bMLH1/bMS Count
H2
% within CA
Type Accdg. to
SG-A
Total

Count
% within CA
Type Accdg. to
SG-A

BRCA1/STK11/L
KB1
Total
312
691
45.2%
100.0%

264

505

769

34.3%

65.7%

67

164

29.0%

71.0%

100.0%

710
42.0%

981
58.0%

1691
100.0%

100.0%

231

Table 12.1
Prev1*Variables in the Equation
B
Step 1

a

Male (1)

S.E.

Wald

df

Sig.

.905 .106 72.231

1

.000

3.343

3

.342

Smoking Status

Exp(B)
2.472

Current-Smokes Everyday (1)

.262 .200

1.730

1

.188

1.300

Current-Smokes Some Days (2)

.341 .349

.952

1

.329

1.406

Former Smoker (3)

.144 .112

1.658

1

.198

1.155

-.349 .082 18.169

1

.000

.705

1

.935

1.017

Age
Constant

.017 .210

a. Variable(s) entered on step 1: Gender, Smoking Status, Age.

.007

83
Table 12.2
Prev1*Omnibus Tests of Model Coefficients
Chi-square
Step 1

df

Sig.

Step

99.758

5

.000

Block

99.758

5

.000

Model

99.758

5

.000

Table 12.3
Prev1*Model Summary

Step

-2 Log likelihood

1

Cox & Snell R

Nagelkerke R

Square

Square

2187.683a

.057

.077

a. Estimation terminated at iteration number 3 because parameter
estimates changed by less than .001.

Positive Predictive Value: Prev1
=100 x (314/248+314)
= 100 x (314/562), =100 x 0.5587
= 55.9%. That is, of all cases predicted as having P16(CDKN2A)/PRSS1 genes that
could directly cause the initiation of PC and other CTSG-A, 55.9% were correctly
predicted.
Negative Predictive Value: Prev1
= 100 x (752/752+377)
= 100 x (752/1,129)
= 100 x .6660
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= 66.6%. That is, of all cases predicted as not having the genes directly responsible for
the development of PC and other CTSG-A, 66.6% were correctly predicted.
Table 12.4
Prev1*Classification Tablea
Predicted
Prev1
BRCA1/ST
K11/LKB1/
bMLH1/bM P16(CDKN2A
SH2
)/PRSS1
752
248

Observed
Step 1 Prev1

BRCA1/STK11/LKB1/b
MLH1/bMSH2 = No
P16(CDKN2A)/PRSS1 =
Yes
Overall Percentage

377

Percentage
Correct
75.2

314

45.4
63.0

Table 12.5
Prev2*Variables in the Equation

Step 1

a

Male (1)

B

S.E.

Wald

df

Sig.

Exp(B)

-.553

.105

27.881

1

.000

.575

3.562

3

.313

Smoking Status
Current-Smokes Everyday (1)

-.250

.198

1.584

1

.208

.779

Current-Smokes Some Days (2)

-.109

.346

.100

1

.752

.896

Former Smoker (3)

-.179

.109

2.702

1

.100

.836

Age

.242

.080

9.121

1

.003

1.274

Constant
-.467 .208
5.063
a. Variable(s) entered on step 1: Gender, Smoking Status, Age.

1

.024

.627
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Table 12.6
Prev2*Omnibus Tests of Model Coefficients
Chi-square
Step 1

df

Sig.

Step

44.897

5

.000

Block

44.897

5

.000

Model

44.897

5

.000

Table 12.7
Prev2*Model Summary

Step

-2 Log likelihood

1

Cox & Snell

Nagelkerke

R Square

R Square

2285.464a

.026

.035

a. Estimation terminated at iteration number 3 because
parameter estimates changed by less than .001.

Positive Predictive Value: Prev2
= 100 x (395/353+395)
= 100 x (395/748)
= 100 X .5280
= 52.8%. That is, of all cases surveyed to have PC and other CTSG-A, the probability of
having the BRCA1, STK11, and LKB1 genes have 52.8% positive predictive value.
Negative Predictive Value: Prev2
= 100 x (569/569+374)
= 100 x (569/943)
= 100 x .6033
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=60.3%. That is, of all cases predicted as not having SG-A, 60.3% were correctly
predicted.
Table 12.8
Prev2*Classification Tablea
Predicted
Prev2

Observed
Step 1
Prev2

P16(CDKN2A)/PRSS1/bM
LH1/bMSH2 = No

P16(CDKN2
A)/PRSS1/b
MLH1/bMS BRCA1/STK11/
H2
LKB1
569
353

BRCA1/STK11/LKB1 =
Yes

374

Percentage
Correct
61.7

395

51.4

Overall Percentage

57.0

a. The cut value is .500

Table 12.9
Parameter Estimates and Odd Ratios
Prev1
Independent Variable
Step 1

a

Male (1)

B
-.553

Smoking Status

Sig.
.000

Prev2
Exp(B)

B

.905

.905

Sig.
.000

Exp(B)
2.472

.342

.313

Current-Smokes Everyday (1)

-.250

.208

.262

.262

.188

1.300

Current-Smokes Some Days (2)

-.109

.752

.341

.341

.329

1.406

Former Smoker (3)

-.179

.100

.144

.144

.198

1.155

Age

.242

.003

-.349

-.349

.000

.705

Constant

-.467

.024

.017

.017

.935

1.017

a. Variable(s) entered on step 1: Gender, Smoking Status, Age.
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Summary
The effect of tobacco use, age, and sex in the etiopathogenesis of PC and CTSGA was assessed using cumulative odds ordinal logistic regression with proportional odds.
While the results of this study supported the null hypotheses that smoking has no
correlation with the prevalence of PC and CTSG-A as confirmed by the GENLIN
parameter estimates, both gender and age are statistically significant predictors with <.05
p-values. The odds of male respondents developing PC and CTSG-A versus the female
respondents is .418 (95% Cl, .344 to .509) with a statistically significant effect, X2 (1) =
75.507. The odds ratio of 1.374 (95% CI, 1.184 to 1.595), Wald χ2(1) = 17.538 is
suggestive to the increased probability of developing the disease as the person reach the
age between 62 and 69 years of age. The findings of this dissertation support the results
of Ellison (2017) that the age-specific pattern of PC tends to be at age 60, and 4 in 5 cases
during 2011 to 2013 were 70 and older. Likewise, separate binomial logistic regression
analysis shows age was associated with an increased likelihood of developing the disease.
Analogous to the results of the ordinal logistic regression analysis, the odds of the male
participants of the 2014 BRFSS survey is 2.472 times greater to develop the disease as
opposed to female respondents. Further discussion of the results of this study and its
implication for connecting the association of tobacco use, gender, and age in the initiation
of PC and CTSG-A will be presented in chapter 5. In addition to a discussion of the
positive social impact, the following chapter will review potential lines of inquiry for
future research.
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Chapter 5: Discussion, Conclusions, and Recommendations
Overview
Pancreatic cancer has become the third leading cause of cancer-related death, with
little improvement in mortality and outcomes despite decades of research (Dreyer,
Chang, Bailey, & Biankin, 2017; Lucas et al. 2016). The need to acknowledge continued
research is critical to recognize the importance of establishing meaningful, evidencebased risk prediction models that could be applied in clinical settings to improve the
accuracy of early identification of premalignant lesions as part of a personalized
therapeutic approach. Although regular smoking was confirmed as a significant risk
factor in both sexes by Andersson, Wennersten, Borgquist, and Jirström (2016), the
association between smoking intensity and duration was not statistically significant in the
current study. Drawing conclusions about smoking and family history can be complicated
because both commonly track in the same family and it is difficult to differentiate the
genetic component from the carcinogen exposure using BRFSS data. The likely impact of
improved understanding of the etiopathogenic role of gender and age and the
pathopoiesis mechanism of smoking to PC and CTSG-A prompted the current study.
A cross-sectional design was used to understand environmental, genetic, and
biodemographic interactions (EGBIs) and generate hypotheses for future research. The
purpose of the study was to establish the existence or absence of correlation between
tobacco use, gender, and age in the etiopathogenesis of PC/CTSG-A, with the intent of
enhancing the understanding of EGBIs in disease evolution (induction, promotion, and
expression periods). The following research questions and hypotheses were addressed:
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RQ1: Is cigarette smoking associated with the etiopathogenesis of pancreatic
cancer and cancer types with shared gene association (CTSG-A)?
H01: Smoking level has no correlation with the prevalence of PC and CTSG-A.
H1: Smoking can increase the risk of PC and CTSG-A.
RQ2: Is there a relationship between the combined role of age and gender in the
etiopathogenesis of PC and CTSG-A?
H02: Age and gender have no correlation with the prevalence of PC and CTSG-A.
H2: Age and gender are correlated with the prevalence of PC and CTSG-A.
Cumulative odds ordinal logistic regression with proportional odds was run, and
two separate binomial logistic regression analyses were performed to determine the
effects of age, gender, and smoking level among participants with P16(CDKN2A)/PRSS1
genes and BRCA1/STK11/LKB1 genes on the likelihood of developing PC and CTSG-A.
After passing the first two ordinal logistic regression assumptions, the third assumption
(zero multicollinearity) was confirmed by running the linear regression procedure. Based
on the coefficient table, the tolerance values were greater than 0.1 (the lowest was .349),
and all of the variance inflation factors were much less than 10, indicative of zero
multicollinearity problems. The presence of proportional odds (Assumption 4) was
assessed by a full likelihood ratio test. Results of the study indicated zero correlation
between tobacco use and the prevalence of PC and CTSG-A. Both gender and age were
statistically significant predictors of PC and CTSG-A evolution.
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Discussion
Germline Genetic Alterations
Pancreatic cancer (PC) is a disease of inherited (germline) and somatic gene
mutations (Maitra & Hruban, 2008). In the current study, cancer types of the 2014
BRFSS cancer survivorship module were grouped based on germline genetic alterations
that had been recognized and summarized by Maitra and Hruban as having been
associated with an increased risk of pancreatic cancer. Of the 28 cancer types surveyed in
the 2014 BRFSS, there were 16 cancer types in the cancer survivorship module known to
have a shared-gene association (SG-A). These 16 cancer types were grouped based on
germline mutation genes to establish levels of the dependent variable: 1=
P16(CDKN2A)/PRSS1, 2 = BRCA1/STK11/LKB1, 3 = bMLH1/bMSH2.
Multicollinearity and the Increased Likelihood of Developing the Disease
I created dummy variables to test for the assumption of multicollinearity, and
created dichotomous cumulative categories of the levels of the dependent variable
required for the assumption of proportional odds and to run diagnostics that were critical
in setting up the data set to run an ordinal logistic regression. Dichotomous cumulative
categories (Prev1, Prev2) of the levels of the dependent variable were created and
recoded as follows:
Prev1 = 0 (all other values: BRCA1/STK11/LKB1/bMLH1/bMSH2), 1
(P16(CDKN2A)/PRSS1);
Prev2 = 0 (all other values: P16(CDKN2A)/PRSS1/bMLH1/bMSH2), 1
(BRCA1/STK11/LKB1).
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The logistic regression model was statistically significant, χ2(5) = 99.758, p <
.0005. The model explained 7.7% (Nagelkerke R2) of the variance in the outcome
variable and correctly classified 63.0% of cases. Sensitivity was 45.4%, specificity was
75.2%, positive predictive value was 55.9%, and negative predictive value was 66.6%. Of
the three predictor variables, gender and age were statistically significant. Increasing age
was associated with an increased likelihood of developing the disease. Gender with a p
value of .000 and age with a p value of .000 added significantly to the model/prediction
compared to smoking status. Male respondents had 2.472 times greater odds to develop
the disease as opposed to female respondents. Among participants with
BRCA1/STK11/LKB1 genes, binomial logistic regression analysis indicated the effects
of age, gender, and smoking level on the likelihood of developing PC and CTSG-A. The
logistic regression model was statistically significant, χ2(5) = 44.897, p < .0005. The
model explained 3.5% (Nagelkerke R2) of the variance in the outcome variable and
correctly classified 63.0% of cases. Sensitivity was 51.4%, specificity was 61.7%,
positive predictive value was 52.8%, and negative predictive value was 60.3%. As in
participants with P16(CDKN2A)/PRSS1 genes, two predictor variables (gender and age)
among participants with BRCA1/STK11/LKB1 genes were statistically significant.
Increasing age was associated with an increased likelihood of developing the disease.
Gender with a p value <.0005 and age with a p value of <.0005 added significantly to the
model/prediction compared to smoking status. Male respondents had a 57.5% likelihood
to develop the disease, a statistically significant effect, X2 (1) = 75.507, p-value < .0005
with .418 (95% Cl, .344 to .509) times that of female respondents.
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Proportional Odds Model and Cumulative Odds Ordinal Logistic Model
Cumulative odds ordinal logistic regression with proportional odds was run to
determine the effect of tobacco use, age, and gender in the etiopathogenesis of PC/CTSG.
The assumption of proportional odds was met, as assessed by a full likelihood ratio test
comparing the fit of the proportional odds model to a model with varying location
parameter, X2(5) = 6.497 with a p value of .261. The percentage of cells with zero
frequency was 5.8%; therefore, 94.2% of expected cell frequencies were indicative of the
reliability of overall goodness-of-fit measures. Both the Pearson and deviance goodnessof-fit indicated that the model was a good fit to the observed data, X2(39 [Pearson], 39
[deviance]) = 38.011 [Pearson], 41.325 [deviance], with p values of .515 and .369,
respectively. The final model significantly predicted the dependent variable over and
above the intercept-only model, X2(5) = 99.090 with a p value < .001. Although the
GENLIN parameter estimates showed that smoking status was not significantly
associated with the outcome, both gender and age were significant predictors. The odds
ratio of male respondents developing PC and CTSG-A compare to female respondents
was .418 (95% Cl, .344 to .509) with a statistically significant effect, X2 (1) = 75.507, p
value < .0005.
Although the Pearson chi-square results showed Prev1 and Prev2 smoking level
was statistically significant, cumulative odds ordinal logistic regression showed higher p
values compared to age and gender. An increase in age (expressed in years) was
associated with an increase in the odds of developing PC/CTSG-A, with an odds ratio of
1.374 (95% CI, 1.184 to 1.595), Wald χ2(1) = 17.538, p < .0005. Likewise, the Tests of
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Model Effect showed that smoking status was not a significant predictor. The
respondent’s gender was a statistically significant predictor of PC/ CTSG-A with a p
value <.05, Wald X2(1) = 75.507 indicating statistically significant predictor effect.
Limitations
When I started this study, my initial intent was to analyze data from Johns
Hopkins University National Familial Pancreas Tumor Registry (NFPTR) to address my
research questions and hypotheses. The data-driven approach and the research question
approach are the two general approaches for analyzing existing data (Cheng & Phillips,
2014). According to Cheng and Phillips (2014), these two methods are often used jointly
and interactively. Using NFPTR secondary data, the research question approach was
more appropriate, but because of the time and challenges involved in establishing an
inter-institutional relationship, I decided to move on with analyzing the data from the
2014 BRFSS. Although my approach remained research question driven, I also
incorporated a data-driven approach and revised my research questions and hypotheses so
they could be answered by the available data. However, BRFSS data are not as good and
thorough as NFPTR data. This may have influenced the validity of my findings.
In secondary data analysis, there are some limitations that need to be addressed.
Firstly, missing values that could be caused by skip patterns in long and comprehensive
surveys like BRFSS are common to reduce interviewer-interviewee burden and burn-out
by skipping a group of questions that are not relevant for a particular respondent. After
data cleaning, the variables in this dissertation are the only data that can generate
statistically significant results and pass the assumptions of the statistical model used in
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the analysis. Secondly, while using both ‘data-driven’ approach’ and the ‘research
question-driven’ approach, the limitations of using secondary data resulted in the mixed
statistical outcome of the association of smoking to cancer evolution. Given that 51.8%
of the respondents are non-smokers after data cleaning (see Table 4B.2) could explain
why the results of non-parametric tests (Chi Square tests) are statistically significant (see
Appendix D and E) compared to the results of the ordinal logistic regression. Lastly,
given that probability sampling in this dissertation was done using stratified random
sampling by framing the surveyed cancer types by shared genes association, it is hard to
draw conclusions about smoking and family history in association to the genetic
component from the carcinogen exposure. This research endeavor can be initiated using a
registry data from NFPTR, but not with current BRFSS modules. Therefore, it critical to
revise existing BRFSS modules, adding cancer specific modules with the history of
cancer mortality within the family tree genealogy that includes whole-genome
sequencing (WGS) information. Such revision could compliment future studies using
registry data, and the development of the epidemiological-genealogical tree,
complimentary to cancer specific risk history diagnosis scale.
Implications for Social Change
Precision medicine may not be synonymous with whole-genome sequencing
(WGS), but the application of genomic technologies could promote positive social
change on embracing the promise of WGS in healthy people. The key strategy in using
WGS is to tailor care to minimize harm to individuals through anticipatory counseling in
the face of the untargeted nature of the potential findings (Lindor, Thibodeau, & Burke,
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2017). This 2017 study further stated that the utility of “next-generation” sequencing had
been found to establish the diagnosis for hundreds of genetic disorders, to assess
pharmacogenomic variants, and to identify treatable targets within malignant neoplasms.
Given that gender and age are the statistically significant predictors in this dissertation
versus tobacco use, it is paramount to discuss its role, parallel to the overall recognition
of the WGS’s potential benefits as the ultimate genetic test. Benefits include the
satisfaction in knowing more about one’s genome, or the with WGS in healthy people
may include disappointment in how little is interpretable (Dewey et al., 2014; Lindor et
al., 2015).
In addition to smoking cessation discussed in previous chapters, the results of this
dissertation have several implications for social change, such as recognizing cultural
values in developing effective communication structured from the statistically significant
etiopathogenic role of gender and age in the development of PC and CTSG-A. This will
give a clear understanding of what to ask, and what actions to take, allowing the family to
openly explore treatment alternatives during the terminal phase of the illness (BallardReisch & Letner, 2003). Primary prevention must be prioritized as an integral part of
global cancer control. According to Vineis et al., (2014), primary prevention has several
advantages: the effectiveness could have benefits for people other than those directly
targeted, avoidance of exposure to carcinogenic agents is likely to prevent other noncommunicable diseases, and the cause could be removed or reduced in the long term
through regulatory measures against occupational or environmental exposures such as
environmental tobacco smoke (ETS). However, no regulatory standards nor advanced
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innovations could change the hearts and minds of the general population unless evidencebased studies support it. Social change will be dependent upon the continued
dissemination of current cancer research built on integrative social molecular
pathological epidemiology (MPE). While remarkable progress has been made in the last
decade in advanced technology and new methods for biologic measurements; the
reductionist approach of modern epidemiology often remits the principal causes of
disease. Pearce (1996) argue that epidemiology must reintegrate itself into public health
and must rediscover the population perspective. However, while the new paradigm of
downstream (individual) approach could produce a lifestyle approach to social policy, the
cumulative outcome of research in cancer epidemiology could equate positive
implications to population health.
It is important to acknowledge the promise of the holistic approach to improving
health behaviors through health literacy among vulnerable groups that were found to be
an increased risk of developing PC. Complimentary to the statistical outcome of this
dissertation, Clouston, Manganello, and Richards, (2017) found that women have higher
health literacy than men. Moreover, given that an increase in age was associated with the
odds of developing PC/CTSG-A, a holistic approach should be focused not only on the
adults but also the younger members of families and communities (Clauston et al., 2017).
According to Kumar et al. (2012), the attainment of the highest possible standard of
health depends on a comprehensive, holistic approach which goes beyond the traditional
curative care, involving communities, health providers, and other stakeholders. The
challenges due to the changing scenarios such as demographic and epidemiological
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transition, proven by the statistical outcome of this dissertation, amplifies the need for
newer, innovative approaches that are multisectoral, adequately funded, evidence-based
health promotion program with community participation. The global acceptance that
health and social well-being are determined by many factors which are outside the health
system that requires modification of the complex socioeconomic determinants of health,
targeting the complex socioeconomic and cultural changes at family and community
levels (Kumar and Preetha, 2012).
The argument on the gene-environment interaction paradigm to genome-wide
studies in relation to the development of a public issue was discussed in the 2014 study of
Boardman et al., highlighting the importance of integrating social and genetic
perspectives in enhancing findings for both biologically and socially focused research
such as the causality of active and passive smoke exposure to lifetime risk of a fetus to
develop a lethal disease like PC. For decades, behavior geneticists have been working to
disentangle the genomic component of family risk from the social and behavioral
component. According to Boardman et al., understanding the genomic component in
combination with specific environmental contexts could provide the pertinent
information about an individual’s likelihood of exhibiting a particular behavior at a given
time, critical not only to social and genetic epidemiologists, but to the understanding of
the causes, modifiable behavioral risk and adjustable predictors in the development of the
disease. New evidence for genetic influences on most health behaviors, new statistical
methods, and new genetic data sources could help confirm the significance of
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environmental influences on individual’s genetic composition that could be contingent on
the social environment in which one resides, works, and plays.
The mutually advantageous conjunction of viewing positive social change in
cancer epidemiology beyond genetics and social inequalities, the continued technical
advancement to gauge host resistance at a molecular level before the onset of disease and
within the healthy social ecology will lead to human vitality and physiological resilience
(Cole, 2013). Moreover, in combination with the conceptual advances of a network-level
metagenomic approach to people’s health, Cole (2013) emphasized its weight in
accelerating the ongoing transformation of public health from a disease-reactive model to
a more proactive and health-centered approach. While genome-wide analysis can
hypothesize links to environmental sensitivity via biologically plausible networks
(Duncan et al. 2010), positive social change is critical to the continued interest and
openness in knowing about one’s genetic makeup that holds sufficient information
enough to construct a priori disease-specific genetic profiles (Boardman et. al, 2014).
Recommendations for Action
Cancer is a growing global problem and is increasing in the proportion of the
burden among low income and middle-income countries. The pattern can be blamed on
demographic change and to transition in risk factors, but can be preventable by present
knowledge of risk factors. In early 2000, PC incidence rates have been approximately
stable in many European countries, overall trends in USA, Japan, and Australia are likely
to improve in the next future with more favorable trends among young adults from 30 to
49 years old (Bosetti et al., 2012b). Pancreatic cancer has the lowest 5-year relative

99
survival rate, and treatment for metastatic pancreatic cancer are minimally effective. Ma,
Siegel, & Jemal (2013) noted that the complex patterns about death rate trends for
pancreatic cancer remain unexplained by known risk factors. Given that there are only
20% of patients diagnosed with the disease are eligible for surgical resection (Spanknebel
& Conlon, 2000); it is paramount to rationalize the importance of the development of
public health policies designed in lowering the economic burden of the disease. Money
saved from reducing the overall economic burden of the disease could open up resources
and funding allocation to pursue other public health projects for the better good of the
many.
Environmental tobacco smoke (ETS) is an example of environmental exposure
that has been associated with an array of adverse effects on health. Secondhand smoke,
referred to as ETS, contains many of the same carcinogenic compounds as the
mainstream smoke inhaled by active smokers (World Health Organization, International
Agency for Research on Cancer, 2004; Bao et al., 2009). Under the lens of public health,
quitting smoking could decrease the incidence of PC, by protecting vulnerable members
of the population. The rapid uptake and use of new health information among vulnerable
groups, and access to health-enhancing treatment and technologies will be dependent
upon the development and implementation of public health policies that include equitable
allocation of resources to every enclave of the community. While the past and current
research could help continue the improvement of the accuracy of passive smoking
measurement, it is critical for the continuance of applying the exposome concept to
environmental health problems. Research outcomes that help the drafting of amendments
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to policies and approaches, built on existing policies such as cigarette labeling acts,
smoking bans, and distribution of cessation tools will not only improve mortality level of
the disease but population health as a whole.
One of the greatest challenges and opportunities for 2016 is to intensify the
implementation of evidence-based path-breaking interventions in modifying major risk
factors for chronic diseases such pancreatic cancer beyond genetics and social
inequalities. According to Halpin et al. (2010), delivering interventions at the level of
society using the paradigm of the New Public Health can change the environment, and
individual behaviors through public health policy, and focus beyond genetics and social
inequalities. It is critical to acknowledge the burden of PC and the assessment of the
current state of research on this issue, shedding light on the critical significance of
environmental epidemiology in protecting vulnerable subgroups of populations from
environmental hazards and its causal association on induction and promotion of
pancreatic cancer. The burden of chronic diseases such PC is often ignored on the public
agendas at both the individual and community level, albeit most public health
interventions focus on induction and promotion (Haplin et al., 2010). While the
correlation of smoking is statistically significantly weak in this dissertation, the biggest
single cause of cancer is tobacco use. Therefore, it is paramount to embrace the concept
of precision medicine in integrating molecular pathology, epidemiology, and social
science.
The evolving transdisciplinary field of molecular pathological epidemiology
(MPE), could better connect the dots of the pathopoiesis mechanism of smoking and
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shared genes in pancreatic cancer, as well as integrate molecular analysis into social
epidemiology for deeper insights on social influences on pathogenic processes (Nishi et
al., 2016). According to Colditz, Wolin, and Gehlert (2012), better implementation of
lessons learned in this dissertation could contribute to achieving maximal possible cancer
prevention, to counter the projected doubling of cancer cases diagnosed by 2050
(Edwards et al., 2002). While molecular window into the body could help guide public
health interventions and social policies to more proactively address the general host
resistance factors that seem to precipitate multiple diseases (Miller, Chen, & Cole, 2009),
lessons learned from studies that link specific gene expression profiles to disease
vulnerability could help gauge the toxicity of various social or geographic environments
or the success of public policies and interventions (Cole, 2013). As some researchers
argue the complexity of exploring the assumption that smoking and family history, both
commonly track together in the same family and differentiating the genetic component
from the carcinogen exposure may be difficult or even impossible without exploring its
molecular window, or limited access to established registry data, it is important to
consider revising current BRFSS cancer survivorship module. Such revision could open
the opportunity for an inferential risk and cancer-specific profiles. Furthermore, an
additional module on sleeping habits and patterns in Expanded BRFSS could connect the
dot on its association with higher body weight or obesity that is known to be a behavioral
risk factor in cancer evolution (Donohoe, Lysaght, O’Sullivan, & Reynolds, 2017).
The cloud created by the present administration’s goals of the “FY 2018 skinny
budget” that was widely condemned by scientists and public health advocates is the deep
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cuts in medical research and health care (Lewis-Burke Associates, 2017). This initial
funding blueprint would weaken public health ad nauseam, as much of the health safety
net formed by the Department of Health and Human Services, the Centers for Medicare
and Medicaid Services, the Centers for Disease and Prevention (CDC), and the National
Institutes of Health (NIH). What can we do to offset the ramifications of the Trump
budget? The deplorable truth is that if this budget were enacted, will not only result in
cancers and diseases going undetected, but the future of scientists and academics who
work so hard to reverse mortality rate, and economic burden. Infectious diseases, and
current public health issues that include bioterrorism, and violent radicalization will not
be deterred by a proposed enhanced wall in our borders.
Recommendations for Future Research
One of the major obstacles confronting funding research and public health
projects is the failure to connect the dots between the significance of continued
investigation on innovative cancer management and raising general public awareness on
cancer problem and control. Improving the future of individuals diagnosed with
pancreatic cancer (PC) through the concerted efforts of policymakers, public health
professionals, clinicians and scientists, the Recalcitrant Cancer Research Act of 2012 lays
the foundation for a heightened focused on further development and use of prevention,
screening and therapeutic strategy (Rahib et al., 2014). Introduced initially as the
Pancreatic Cancer Research and Education Act, the Recalcitrant Cancer Research Act
was signed into law as part of the National Defense Authorization Act on January 2,
2013, through broad bi-partisan and bi-cameral support (The pancreatic cancer action
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network, 2013). The genuine progress against PC as recalcitrant cancer warrants strategic
direction and guidance on the continued understanding, development of efficient early
detection strategy and identifying therapeutic targets that could stem the tide of its
growing economic burden.
Continued research on the association between passive smoking exposure and the
disease, as well as early shared exposure of these predictors, are critical to broadening the
understanding of its significance to lifetime increased risk. The focus on obtaining a
larger number of endpoints, it is paramount for future research to combine more cohorts
to have a stronger and standardized sampling that yields a statistically significant
assessment of predictors associated with pancreatic cancer. A synergy begets by
outcomes research and epidemiology can provide unique and compelling insights on the
significance of interventions designed to improve the quality and effectiveness of care in
populations. It is important to acknowledge the need for continued research to establish a
meaningful risk prediction models that could be practically applied in clinical settings to
raise the accuracy of predicting the potential for PC. Given that surgical resection
procedure is the only treatment approach that could improve survival rate, establishing a
high-risk prediction model using novel early identification protocol of pre-malignant
lesions and molecular profiling, as part of a personalized therapeutic approach and
standardized methods of early detection, and prevention.
Pancreatic cancer (PC) involves both genetic and environmental factors, and like
any other human diseases, PC is complex and multifactorial that has the greatest burden
on society. According to Bookman et al. (2011), the development of high-density
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genotyping platforms has allowed investigators to screen hundreds of thousands of
genetic variants to test for associations with disease (p.2). Hindorff et al. (2011) asserted
that to date, Genome Wide Association Studies (GWAS) have identified over 900
statistically significant findings in various diseases and conditions. While there is much
work still needed to develop practical, ethical, useful policies on GWAS, it is imperative
to embolden researchers in the continued exploration of genetic and environmental
interactions associated with PC and CTSG-A that may identify additional risk factors or
what proportion of cancer induction, promotion, expression is induced by inherited
predisposition or combination of shared environmental, and biodemographic factors.
Future research on the predictive value of whole-genome sequencing (WGS) in the
healthy population is critical on the hypothesis of meaningful information that sheds light
on individual differences in environmental sensitivity that will give summary information
across a number of different loci may prove to be useful (Boardman et al., 2014; Lindor,
Thibodeau, & Burke, 2017). The mechanism(s) through which environmental, genetic,
biodemographic interaction (EGBI) with the particular focus on the effect of tobacco
carcinogens as a shared environmental factor to shared genetic footprints in family cancer
history (FCH) or its combined role remains unknown. Henceforth, it is critical to explore
their correlation in future research, satisfying the sense of urgency for novel and
innovative therapeutics. As stated by Lu et al. (2017), continued understanding of
genomic variations in PC is crucial in providing an avenue for precision medicine. As
emphasized by Lu et al. (2017), sustained understanding of genomic variations in PC is
vital in providing an avenue for precision medicine. It is essential to highlight the

105
significance of these studies in providing fundamental knowledge for new and effective
treatment strategies.
Conclusion
Pancreatic cancer has the global ranking of 13 as the most common cause of
cancer and represents the 7th most frequent cause of cancer death, and accounts for about
3% of all cancers in the US with cancer mortality of 7% (American Cancer Society, Inc.,
2016). These statistics justify the intent of this dissertation to determine whether there is
existence or absence of correlation between tobacco use, gender, and age in the
etiopathogenesis of PC and other cancer types with shared-gene association (CTSG-A),
with the intent of advancing the existing body of knowledge on environmental, genetic
and biodemographic interactions (EGBIs) in cancer evolution. While the results of this
study supported the null hypotheses that smoking has no correlation with the prevalence
of PC and CTSG-A, both gender and age are statistically significant predictors that
supports the need for future research on the modification effect of shared environmental
factors and etiopathogenic role of biodemographic factors (age, gender, race,
socioeconomic status) in cancer evolution.
Ab-initio studies have established that family history of PC can manifest due to
genetic factors and shared environmental factors. The scientific perspective of this
dissertation, current, and past studies are parallel to Albert Einstein’s concept of “natura
naturans”—everything is connected. In this dissertation, the assumption that
P16(CDKN2A), PRSS1, BRCA1, STK11, LKB1, bMLH1, and bMSH2 are correlated
with the development of the disease is mathematically or statistically correct and deserves
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further investigation. The results provided the rationale for further research on the
pathopoiesis mechanism of shared environmental and genetic factors that are responsible
for pancreatic cancer and other CTSG-A evolution. Such molecular window could initiate
evidence-based discussions on the urgent need to revise or improve the BRFSS cancer
survivorship module. While our understanding of the molecular events underlying multistep carcinogenesis in PC has steadily increased (Lu et al., 2017), according to “Analysis
of the President’s FY 2018 Budget Request for Federal Research, Health, and Higher
Education Programs” (2017), “the current administration’s budget blueprint would reduce
funding for Chronic Disease Prevention and Promotion at the CDC by about $164
million” (p. 27). For decades, the federal government has committed to the advancement
of science and population health. It is not our duty to participate in a partisan debate, but
rather protect our long history of closing the gap to equal access to quality health care
through evidence-based studies. It is important to recognize the much-needed focus on
policies that will promote broader population health, as well as potential public policies
that could improve health behaviors easier, particularly for those who belong to
vulnerable, high-risk groups. The assumption of the association of modifiable risk factors
and CPG using the unified paradigm of cancer causation, or the probability of precise
measurement of a risk factor that wakes up dormant mutated cancer genes using
conceptual epidemiological quantum framework will be dependent upon access to cancer
registry data.
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Appendix A
Genetic Alterations in Common Neoplasms of the Pancreas
TUMOR TYPE

GENE(S)

PREVALENCE OF
THE ALTERATION

Acinar cell carcinoma

APC

15%

Acinar cell carcinoma

5%

KRAS

95%

p16/CDKN2A
TP53
SMAD4

95%
75%
55%

MLL3, TGFBR2,
FBXW7, ARID1A,
AIRID2, and ATM

<5%

KRAS
RNF43

80%
75%

GNAS

60%

p16/CDKN2A

Varies dependent on
histologic grade

TP53

Varies dependent on
histologic grade

Associated with higher
grade lesions

SMAD4

Varies dependent on
histologic grade

Associated with higher
grade lesions

PIK3CA
KRAS

10%
75%

Invasive ductal
Adenocarcinoma

IPMN

MCN

COMMENT

KRAS mutations occur
early, and KRAS
mutations may be a
target for early
detection

SMAD4 loss
associated with poor
prognosis and
widespread disease
Some of these, such as
ATM, may
be targetable
therapeutically

RNF43 is a marker of
mucin-producing
tumors because it is
present in both
IPMNs and MCNs
GNAS is a marker of
IPMNs. GNAS
and/or KRAS
mutations are present
in >95% of all IPMNs
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RNF43

40%

p16/CDKN2A

Varies dependent on
histologic grade

TP53

Varies dependent on
histologic grade

Associated with higher
grade lesions

SMAD4

Varies dependent on
histologic grade

Associated with higher
grade lesions

Imprinted region
on chromosome 11

85%

Same region is targeted
in hepatoblastoma
and Wilms tumors

CTNNB1
(beta-catenin)

55%

APC
MEN1
DAXX or ATRX

10%
45%
45%

TSC2, PTEN, and
PIK3CA (mTOR
pathway genes)

15%

Potentially targetable
therapeutically
with everolimus

SCN

VHL

50%

SPN

CTNNB1
(beta-catenin)

95%

Among the cystic
tumors of the pancreas,
VHL loss is specific
for SCN
Immunolabeling for
beta-catenin is
useful diagnostically

Pancreatoblastoma

PanNET

RNF43 is a marker of
mucin-producing
tumors, present in
IPMNs and MCNs

Associated with ALT+

ALT+ indicates an alternative lengthening of telomeres; IPMN, intraductal papillary
mucinous neoplasm; MCN, mucinous cystic neoplasm; PanNET, pancreatic
neuroendocrine tumor; SCN, serous cystic neoplasm; SPN, solid-pseudopapillary
neoplasm.
Note: Adapted from “Recent progress in pancreatic cancer” by Wolfgang et al., 2013,
CA: a cancer journal for clinicians, American Cancer Society, 63(5), p. 327. Copyright
2013 American Cancer Society, Inc.
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Appendix B
Cancer (CA) Types Surveyed During the 2014 BRFSS,
Five-States Cancer Survivorship Module
Valid

Breast Cancer

Frequency

Percent

Valid Percent

1178

16.4

16.4

Cervical Cancer

340

4.7

4.7

Endometrial Cancer

178

2.5

2.5

Ovarian Cancer

104

1.5

1.5

Cancer of the Head and Neck

20

.3

.3

Oral Cancer

22

.3

.3

Pharyngeal Cancer

45

.6

.6

131

1.8

1.8

5

.1

.1

Colorectal Cancer

337

4.7

4.7

Esophageal Cancer

13

.2

.2

Liver Cancer

19

.3

.3

Pancreatic Cancer

12

.2

.2

Rectal Cancer

31

.4

.4

Cancer of the Stomach

13

.2

.2

Hodgkin’s Lymphoma

61

.9

.9

Leukemia

73

1.0

1.0

Non-Hodgkin’s Lymphoma

77

1.1

1.1

613

8.6

8.6

25

.3

.3

964

13.4

13.4

2183

30.5

30.5

Lung Cancer

137

1.9

1.9

Bladder Cancer

129

1.8

1.8

Renal Cancer

100

1.4

1.4

Cancer of the Bone

38

.5

.5

Brain Cancer

16

.2

.2

5

.1

.1

Other

300

4.2

4.2

Total

7169

100.0

100.0

Thyroid Cancer
Cancer of the Larynx

Prostate Cancer
Testicular Cancer
Melanoma
Other skin cancer

Neuroblastoma
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Appendix C
CA Type with SG-A Before Data
Cleaning and Re-coding
Valid

Other CA Types with 0-

Cumulative
Frequency

Percent

Valid Percent

Percent

1312

43.7

43.7

43.7

473

15.8

15.8

59.4

Endometrial Cancer

84

2.8

2.8

62.2

Ovarian Cancer

40

1.3

1.3

63.6

8

.3

.3

63.8
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4.7

4.7

68.6

Esophageal Cancer

6

.2

.2

68.8

Pancreatic Cancer

6

.2

.2

69.0

Cancer of the Stomach

5

.2

.2

69.1

Leukemia

27

.9

.9

70.0

Melanoma

460

15.3

15.3

85.3

Lung Cancer

70

2.3

2.3

87.7

Bladder Cancer

49

1.6

1.6

89.3

Renal Cancer

45

1.5

1.5

90.8

Brain Cancer

7

.2

.2

91.0

256

8.5

8.5

99.6

13

.4

.4

100.0

3003

100.0

100.0

Known SG-A
Breast Cancer

Cancer of the Head and
Neck
Colorectal Cancer

Prostate Cancer
Osteosarcoma (Bone)
Total
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Appendix D
Table D1.1
Prev1*Respondents Gender Crosstabulation
Respondents Gender
Male
Prev1

BRCA1/STK11/LKB1/bML Count
H1/bMSH2

Expected Count

P16(CDKN2A)/PRSS1

Count
Expected Count

Total

Count
Expected Count

Female

Total

322

678

1000

409.2

590.8

1000.0

370

321

691

282.8

408.2

691.0

692

999

1691

692.0

999.0

1691.0

Table D1.2
Chi-Square Tests

Value
77.013a
76.133
76.990

df

Asymptotic
Significance (2sided)
1
.000
1
.000
1
.000

Exact Sig. (2sided)

Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher’s Exact Test
.000
Linear-by-Linear
76.968
1
.000
Association
McNemar Test
.c
N of Valid Cases
1691
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 282.77.
b. Computed only for a 2x2 table
c. Both variables must have identical values of categories.

Exact Sig. (1sided)

.000
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Table D2.1
Prev1*Three Age Group Crosstabulation

Prev1

Total

Table 13A: Prev1 * Three Age Group Crosstabulation
Three Age Group
<51
52-69
70>
BRCA1/STK11/LKB1/bML Count
62
369
569
H1/bMSH2
Expected Count
74.5
389.7
535.8
P16(CDKN2A)/PRSS1
Count
64
290
337
Expected Count
51.5
269.3
370.2
Count
126
659
906
Expected Count
126.0
659.0
906.0

Table D2.2
Chi-Square Tests
Asymptotic
Significance (2Value

df

sided)

Pearson Chi-Square

12.876a

2

.002

Likelihood Ratio

12.818

2

.002

Linear-by-Linear

12.869

1

.000

.

.

.b

Association
McNemar-Bowker Test
N of Valid Cases

1691

a. 0 cells (.0%) have expected count less than 5. The minimum
expected count is 51.49.
b. Computed only for a PxP table, where P must be greater than 1.

Total
1000
1000.0
691
691.0
1691
1691.0
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Table D3.1
Prev1*Four-Level Smoking Status Crosstabulation
Four-Level Smoking Status

Prev1

BRCA1/S
TK11/LK
B1/bMLH
1/bMSH2
P16(CDK

Now
Smokes
Everyday

Now Smokes
Some Days

Former
Smoker

Never
Smoked

Total

Count

66

19

362

553

1000

Expected

73.3

21.3

387.3

518.0

1000.0

Count

58

17

293

323

691

Expected

50.7

14.7

267.7

358.0

691.0

Count

124

36

655

876

1691

Expected

124.0

36.0

655.0

876.0

1691.0

Count

N2A)/PRS
S1

Count
Total

Count
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Table D3.2
Chi-Square Tests

Value

df

Asymptotic Significance (2-sided)

Pearson Chi-Square

12.228

a

3

.007

Likelihood Ratio

12.229

3

.007

9.282

1

.002

.

.

.b

Linear-by-Linear Association
McNemar-Bowker Test
N of Valid Cases

1691

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 14.71.
b. Computed only for a PxP table, where P must be greater than 1.

Appendix E
Table E1.1
Prev2*Respondents Gender Crosstabulation
Respondents Gender
Male
Prev2

P16(CDKN2A)/PRSS1/bM

Count

LH1/bMSH2

Expected Count

BRCA1/STK11/LKB1

Count
Expected Count

Total

Count
Expected Count

Female

Total

434

488

922

377.3

544.7

922.0

258

511

769

314.7

454.3

769.0

692

999

1691

692.0

999.0

1691.0
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Table E1.2

Pearson Chi-Square

31.709

a

1

.000

Continuity Correctionb

31.152

1

.000

Likelihood Ratio

31.926

1

.000

Fisher’s Exact Test
Linear-by-Linear

sided)

(2-sided)
Sig. (2Exact

df

Significance

Value

Asymptotic

Chi-Square Tests

Exact Sig. (1-sided)

.000 .000
31.690

1

.000

Association
.c

McNemar Test
N of Valid Cases

1691

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 314.69.
b. Computed only for a 2x2 table
c. Both variables must have identical values of categories.
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Table E2.1
Prev2*Three Age Group Crosstabulation
Three Age Group
Prev2

P16(CDKN2A)/PRSS1/
bMLH1/bMSH2

Count

<51
82

52-69
366

70>
474

Total
922

Expected Count

68.7

359.3

494.0

922.0

BRCA1/STK11/LKB1

Count

44

293

432

769

Expected Count

57.3

299.7

412.0

769.0

Count

126

659

906

1691

126.0

659.0

906.0

1691.0

Total

Expected Count

Table E2.2
Chi-Square Tests
Asymptotic
Significance (2Value

df

sided)

Pearson Chi-Square

7.714a

2

.021

Likelihood Ratio

7.829

2

.020

Linear-by-Linear

6.644

1

.010

.

.

.b

Association
McNemar-Bowker Test
N of Valid Cases

1691

a. 0 cells (.0%) have expected count less than 5. The minimum
expected count is 57.30.
b. Computed only for a PxP table, where P must be greater than 1.
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Table E3.1
Prev2*Four-Level Smoking Status Crosstabulation
Four-Level Smoking Status
Now

Prev2

Smokes

Now Smokes

Former

Never

Everyday

Some Days

Smoker

Smoked

Total

74

20

381

447

922

67.6

19.6

357.1

477.6

922.0

50

16

274

429

769

56.4

16.4

297.9

398.4

769.0

124

36

655

876

1691

124.0

36.0

655.0

876.0

1691.0

P16(CDKN Count
2A)/PRSS1 Expected
/bMLH1/b Count
MSH2
BRCA1/ST Count
K11/LKB1 Expected
Count

Total

Count
Expected
Count

Table E3.2
Chi-Square Tests
Asymptotic
Significance (2Value

df

sided)

Pearson Chi-Square

9.171

a

3

.027

Likelihood Ratio

9.186

3

.027

Linear-by-Linear

6.434

1

.011

.

.

.b

Association
McNemar-Bowker Test
N of Valid Cases

1691

a. 0 cells (.0%) have expected count less than 5. The minimum
expected count is 16.37.
b. Computed only for a PxP table, where P must be greater than 1.

